瑞舒伐他汀对心肌梗死大鼠心功能的影响及其机制
|
摘要
第一部分瑞舒伐他汀对心肌梗死大鼠心功能的影响及其机制
研究背景:
心力衰竭终末期细胞内Ca~(2+)稳态的调节及其病理生理变化主要涉及收缩期Ca~(2+)从肌质网中的释放和肌质网对Ca~(2+)的重新摄取等机制。肌浆网Ca~(2+)-ATP酶(sarcoplasmic reticulum Ca~(2+)-ATPase,SERCA)和磷酸受钙蛋白(Phospholamban,PLB)被认为是主要的心肌收缩/舒张的动态调节蛋白。通过干预使心力衰竭时异常的SERCA和PLB表达恢复的治疗方式有望应用于临床治疗心力衰竭患者。
近年来的一些临床研究显示3-羟基3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂即他汀类药物在心肌梗死后病人中应用可以减少心室重塑,改善心功能。但对其具体机制的研究中关于他汀类是否可以直接影响钙调蛋白的研究很少。
目的:
本课题观察心肌梗死后瑞舒伐他汀长期应用对左室重构和心功能的影响。并在此基础上,研究瑞舒伐他汀是否通过影响心脏的肌浆网钙调蛋白SERCA和PLB的表达而产生对心功能的影响,同时检测心肌白细胞介素-6(interleukin-6,IL-6)和白细胞介素-10(interleukin-10,IL-10)的表达。
方法:
以开胸结扎冠状动脉左前降支的方法建立心肌梗死模型。冠脉结扎一天后,以灌胃方式每天一次给予给药组大鼠10 mg·kg~(-1)的瑞舒伐他汀。对照组和假手术组大鼠以同样方式给予等量蒸馏水。结扎冠脉后第2、4、6、8、10周以超声心动图方法检测左室大小(左室舒张末期内径和左室收缩末期内径,即LVIDd和LVIDs)、左室短轴缩短率(FS)、左室射血分数(EF)和舒张末期左室后壁厚度(LVPWd)。结扎冠脉第2和第10周超声心动图检测大鼠心肌梗死面积,结扎冠脉10周后测定左室血流动力学指标。大鼠处死后,测量左室、右室重量与体重比值、血脂水平、肌浆网SERCA活性、大鼠心肌组织SERCA2a、PLB和16位丝氨酸磷酸化-PLB(pSer16-PLB)蛋白表达水平以及心肌梗死区、梗死周围区和远离梗死区IL-6和IL-10的表达水平。
结果:
10周的瑞舒伐他汀治疗未影响实验各组大鼠的血脂水平和心梗面积。但超声心动图和血流动力学检测结果显示,心肌梗死大鼠予以瑞舒伐他汀10mg·kg~(-1)灌胃给药10周后,左室重构减轻,心功能明显改善。同时,左室心肌降低的SERCA活性、SERCA2a蛋白表达增高,升高的PLB蛋白表达不变,pSer16-PLB蛋白表达升高,降低的pSer16-PLB/PLB比值增加。衰竭心脏左室梗死周围区和远离梗死区升高的IL-6水平降低,升高的IL-10水平进一步升高。
结论:
心肌梗死大鼠予以瑞舒伐他汀10 mg·kg~(-1)灌胃给药10周后,显著改善了左室重构和左室功能。该有益作用并非通过其降脂效应或是改变心梗面积而产生。可能与瑞舒伐他汀治疗可以部分恢复钙调节蛋白的异常表达及对炎症因子的致损伤机制有一定的减轻作用有关。
第二部分藻酸双酯钠对心肌缺血再灌注后心功能的影响及机制探讨
研究背景:
藻酸双酯钠(Polysaccharide sulfate,PSS)是以海藻提取物为基础原料,用化学方法引入有效基团合成的一种新型的类肝素药物。基础和临床研究显示PSS具有抗凝血、降低血粘度、降低TC和TG、升高HDL-C、降低血小板释放、明显的刺激合成PGI_2及改善微循环的功能。临床上有很多种情况会出现心脏暂时性缺血再灌注后心功能下降。基础研究显示PSS对大鼠脑缺血再灌注损伤有保护作用。目前关于PSS对心肌缺血再灌注后心功能影响的研究未见报道。
目的:
本实验应用大鼠心肌缺血再灌注后(Langendorff)模型,评价急性PSS应用能否对缺血再灌注损伤后心脏的心功能产生影响,并在此基础上,研究PSS是否是通过影响心脏丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号转导通路及肿瘤坏死因子-α(TNF-α)的表达而产生对心功能的影响。
方法:
成年雄性Sprague-Dawley(SD)大鼠,随机分成8组:A1组(正常对照组,normalcontrol):给予改良的Krebs-Henseleit(K-H)液灌注60 min;A2组(缺血再灌注对照组,ischemia control):缺血20 min,复灌时给予改良的K-H液灌注60 min;A3-A8组(缺血再灌注PSS给药组,ischemia control plus PSS 0.3,1,3,10,30 or 100):缺血20 min,复灌时给予含0.3,1,3,10,30,100 mg/L PSS的改良K-H液灌注60min。记录心脏收缩舒张功能指标,包括左心室发展峰压(left ventricular灌注developed pressure,LVDP)、左心室舒张末压(left ventricular end diastolic pressure,LVEDP)、左室内压最大上升及下降速率(maximum rate of intraventricular pressuredevelopment and relaxation;+dp/dt max,-dp/dt max)和心率(heart rate)。记录冠脉流量(coronary flow)。收集冠脉流出液,测定其中肌酸激酶(creatine kinase,CK)和乳酸脱氢酶(lactate dehydrogenase,LDH)含量。裂解心脏组织,测定心肌组织TNF-α蛋白含量及MAPK信号转导通路的关键性调控蛋白包括细胞外信号调节激酶(extracellular signal-regulated kinases,ERKs),c-Jun氨基末端激酶(c-junamino-terminal kinase,JNKs)和p38丝裂原活化蛋白激酶(p38 mitogen-activatedprotein kinase,p38 MAPK)的活性。
结果:
1～30 mg/L PSS可以提高缺血再灌注后心脏的LVDP%、+dp/dt max%、-dp/dtmax%和冠脉流量百分比,降低LVEDP%,对心率无明显影响。同时,1-30 mg/L PSS明显降低缺血再灌注后心脏释放的CK和LDH量,降低心肌组织升高的TNF-α水平及升高的p-p38MAPK和p-p54/p46-JNK蛋白表达水平。0.3 mg/L PSS对心脏舒缩功能和冠脉流量、心率、CK和LDH释放、TNF-α水平及p-p38MAPK和p-p54/p46-JNK水平均未产生影响。100 mg/L PSS则使本已受损的心功能进一步恶化,导致心脏舒缩功能、冠脉流量和心率的明显下降。0.3～100 mg/L PSS对P-p44/p42-ERK蛋白表达均为产生明显影响。
结论:
一定浓度的PSS(1～30mg/L)对于缺血再灌注损伤后的心脏,具有提高心脏舒缩功能,减轻心肌细胞损伤,提高冠脉流量而不改变心率等药理效应。该效应可能与减少缺血再灌注损伤所致的TNF-α表达水平的升高,逆转缺血再灌注损伤引起的MAPK通路改变相关。
Part 1 Beneficial effect of rosuvastatin on heart failure is associated with alterations of calcium-regulatory proteins
Background:
The release of Ca~(2+) from sarcoplasmic reticulum(SR) and sarcoplasmic Ca~(2+) reuptake mainly involve in the regulation of intracellular Ca~(2+) homeostasis and its pathophysiological change.Sarcoplasmic reticulum Ca~(2+) ATPase(SERCA) and SERCA regulatory protein phospholamban(PLB) are the key proteins responsible for maintaining Ca~(2+) homeostasis throughout the excitation-contraction coupling cycle in cardiomyocyte.Interfering with the abnormal expression of SERCA and PLB may be a promising method in the clinical treatment of HF patients.
Recent clinical and experimental studies indicated that statins(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) can attenuate ventricular remodeling and improve ventricular function after myocardial infarction(MI).But there are few data exploring whether statins exhibit special effect in improving left ventricular(LV) remodeling and function through influence on calcium-regulatory proteins.
Aim:
We undertook our research to investigate effect of rosuvastatin on LV remodeling and cardiac function in a rat model of HF induced by MI.In addition,tissue levels of SERCA2a,SERCA activity,PLB and pSerl6-PLB as well as interleukin(IL)-6 and IL-10 in myocardium of rats with MI were detected to explore the molecular mechanism.
Methods:
Adult male Sprague-Dawley rats were anesthetized and the left coronary artery was ligated 2 to 3 mm from its origin to induce MI.For sham-operated animals,the suture was placed but not ligated(S group).MI rats were randomized to receive gavage with either 1 ml·day-1 distilled water(MI group) or 10 mg·kg-1·day-1 rosuvastatin dissolved in 1 ml distilled water for 10 weeks(MI+R group).Normal control(NC group) and normal control plus rosuvastatin treatment rats(NC+R group) were randomly selected.Rats were evaluated by echocardiography 2,4,6,8 and 10 weeks after operation.Left ventricle(LV) internal diameter at end-diastolic phase(LVIDd),LV internal diameter at end-systolic phase(LVIDs),LV posterior wall thickness at diastolic phase(LVPWd),LV shortening fraction(FS) and ejection fraction(EF) were measured. Infarct size was also detected by echocardiography 2 and 10 weeks after MI.10 weeks after MI,rats were anesthetized,and hemodynamic variables were measured.After rats were sacrificed,LV relative weight(LVRW) and right ventricular relative weight (RVRW) were obtained,when the LV actual weight(LVAW) and right ventricular actual weight(RVAW) were corrected for body weight.Serum total cholesterol,triglycerides, and low- and high-density lipoprotein cholesterol were measured using enzymatic colorimetric assays.SR was prepared from LV tissue for Determination of SERCA activity.The protein expression of SERCA2a,PLB and phospho-PLB at serine-16 (pSer16-PLB) were detected by western blot.IL-6 and IL-10 levels were assessed by enzyme-linked immunosorbent assay.
Results:
After rosuvastatin treatment,LV remodeling and dysfunction were attenuated. Rosuvastatin partially restored the low expression of SERCA2a and pSerl6-PLB, increased SERCA activity,but showed no effect on PLB expression.Furthermore, rosuvastatin reduced the increased IL-6 level and further elevated IL-10 level in the peri-infarct and remote zones of MI.Serum lipid levels and infarct size remained unchanged.
Conlusions:
Rosuvastatin is effective in reducing LV remodeling and dysfunction in the failing heart.The molecular mechanism may be related to normalization of SERCA2a expression,SERCA activity,and pSerl6-PLB levels,as well as through cytokine alterations independent of its effect of lipid-lowering or MI size reduction.
Part 2 Cardioprotection and mechanisms of polysaccharide sulfate against ischemia/reperfusion injury in isolated rat hearts
Background:
Polysaccharide sulfate(PSS) is a new type heparinoid extracted from Phylum Phaeophyta.By chemically introducing sulfuryl and propylene glycol residues in the hydroxyl and carboxyl group of alginic acid sodium,PSS obtained is a diester sodium. Basic and clinical research showed PSS have the effect of anticoagulation,lowering blood viscosity,decreasing TC and TG,increasing HDL-C,depressing platelet release, stimulating PGI2 synthesis and improving microcirculation.Clinically,there is a sort of myocardial injury,which occurs with transient ischemia followed by re-establishment of flow,and results in prolonged postischemic contractile dysfunction of myocardium. Although PSS is successfully applied in ischemic cardio-cerebrovascular disease,its effect on cardiac function after ischemia/reperfusion(I/R) injury has not been investigated previously.
Aim:
The aim of the present study was to investigate whether acute application of PSS can protect the heart from I/R injury in a model of myocardial I/R of the isolated rat hearts.In addition,the present study is designed to explore whether the cardioprotective effect of PSS is based on the alterations of tumor necrosis factor-a(TNF-α) expression and mitogen-activated protein kinase(MAPK) signal transduction pathway.
Methods:
Isolated rat hearts were perfused(Langendorff) and subjected to 20 min global ischemia followed by 60 min reperfusion with Kreb's Henseleit solution or different concentrations of PSS(0.3～100 mg/L).Myocardial contractile and diastolic function (including left ventricular developed pressure,LVDP;left ventricular end diastolic pressure,LVEDP;maximum rate of intraventricular pressure development and relaxation,+dp/dt max and -dp/dt max) was continuously recorded.Heart rate and the coronary flow were measured.Creatinine kinase(CK) and lactate dehydrogenase(LDH) leakage were measured.Tumor necrosis factor-α(TNF-α) expression by cardiomyocytes was investigated.Western blot analysis for extracellular regulated kinases(ERKs),c-jun amino-terminal kinase(JNKs) and p38 mitogen-activated protein kinase(MAPK) activity were performed.
Results:
PSS administration at concentrations of 1-30 mg/L improved cardiac contractility, reduced CK and LDH releasing and inhibited TNF-αproduction.Phosphorylated-p38MAPK(p-p38MAPK) and p-p54/p46-JNK increased in I/R rat hearts but diminished in PSS(1～30 mg/L) treated hearts.0.3 mg/L PSS had no effect on cardiac contractility,CK and LDH releasing,TNF-αproduction as well as p-p38MAPK and p-p54/p46-JNK expression.In contrast,high concentration of PSS(100 mg/L) had adverse effects that caused worsening of heart function.P-p44/p42-ERK level was unchanged after 0.3～100 mg/L PSS treatment.
Conlusions:
PSS has cardioprotective effect against I/R injury on the rat heart dose-dependently. The beneficial pharmacological effect including improving cardiac performance, increasing coronary flow but not affecting heart rate and lowering cardiocyte injury may be mediated through normalization of p38 MAPK and JNK pathways as well as TNF-αexpression.
研究背景:
心力衰竭终末期细胞内Ca~(2+)稳态的调节及其病理生理变化主要涉及收缩期Ca~(2+)从肌质网中的释放和肌质网对Ca~(2+)的重新摄取等机制。肌浆网Ca~(2+)-ATP酶(sarcoplasmic reticulum Ca~(2+)-ATPase,SERCA)和磷酸受钙蛋白(Phospholamban,PLB)被认为是主要的心肌收缩/舒张的动态调节蛋白。通过干预使心力衰竭时异常的SERCA和PLB表达恢复的治疗方式有望应用于临床治疗心力衰竭患者。
近年来的一些临床研究显示3-羟基3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂即他汀类药物在心肌梗死后病人中应用可以减少心室重塑,改善心功能。但对其具体机制的研究中关于他汀类是否可以直接影响钙调蛋白的研究很少。
目的:
本课题观察心肌梗死后瑞舒伐他汀长期应用对左室重构和心功能的影响。并在此基础上,研究瑞舒伐他汀是否通过影响心脏的肌浆网钙调蛋白SERCA和PLB的表达而产生对心功能的影响,同时检测心肌白细胞介素-6(interleukin-6,IL-6)和白细胞介素-10(interleukin-10,IL-10)的表达。
方法:
以开胸结扎冠状动脉左前降支的方法建立心肌梗死模型。冠脉结扎一天后,以灌胃方式每天一次给予给药组大鼠10 mg·kg~(-1)的瑞舒伐他汀。对照组和假手术组大鼠以同样方式给予等量蒸馏水。结扎冠脉后第2、4、6、8、10周以超声心动图方法检测左室大小(左室舒张末期内径和左室收缩末期内径,即LVIDd和LVIDs)、左室短轴缩短率(FS)、左室射血分数(EF)和舒张末期左室后壁厚度(LVPWd)。结扎冠脉第2和第10周超声心动图检测大鼠心肌梗死面积,结扎冠脉10周后测定左室血流动力学指标。大鼠处死后,测量左室、右室重量与体重比值、血脂水平、肌浆网SERCA活性、大鼠心肌组织SERCA2a、PLB和16位丝氨酸磷酸化-PLB(pSer16-PLB)蛋白表达水平以及心肌梗死区、梗死周围区和远离梗死区IL-6和IL-10的表达水平。
结果:
10周的瑞舒伐他汀治疗未影响实验各组大鼠的血脂水平和心梗面积。但超声心动图和血流动力学检测结果显示,心肌梗死大鼠予以瑞舒伐他汀10mg·kg~(-1)灌胃给药10周后,左室重构减轻,心功能明显改善。同时,左室心肌降低的SERCA活性、SERCA2a蛋白表达增高,升高的PLB蛋白表达不变,pSer16-PLB蛋白表达升高,降低的pSer16-PLB/PLB比值增加。衰竭心脏左室梗死周围区和远离梗死区升高的IL-6水平降低,升高的IL-10水平进一步升高。
结论:
心肌梗死大鼠予以瑞舒伐他汀10 mg·kg~(-1)灌胃给药10周后,显著改善了左室重构和左室功能。该有益作用并非通过其降脂效应或是改变心梗面积而产生。可能与瑞舒伐他汀治疗可以部分恢复钙调节蛋白的异常表达及对炎症因子的致损伤机制有一定的减轻作用有关。
第二部分藻酸双酯钠对心肌缺血再灌注后心功能的影响及机制探讨
研究背景:
藻酸双酯钠(Polysaccharide sulfate,PSS)是以海藻提取物为基础原料,用化学方法引入有效基团合成的一种新型的类肝素药物。基础和临床研究显示PSS具有抗凝血、降低血粘度、降低TC和TG、升高HDL-C、降低血小板释放、明显的刺激合成PGI_2及改善微循环的功能。临床上有很多种情况会出现心脏暂时性缺血再灌注后心功能下降。基础研究显示PSS对大鼠脑缺血再灌注损伤有保护作用。目前关于PSS对心肌缺血再灌注后心功能影响的研究未见报道。
目的:
本实验应用大鼠心肌缺血再灌注后(Langendorff)模型,评价急性PSS应用能否对缺血再灌注损伤后心脏的心功能产生影响,并在此基础上,研究PSS是否是通过影响心脏丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号转导通路及肿瘤坏死因子-α(TNF-α)的表达而产生对心功能的影响。
方法:
成年雄性Sprague-Dawley(SD)大鼠,随机分成8组:A1组(正常对照组,normalcontrol):给予改良的Krebs-Henseleit(K-H)液灌注60 min;A2组(缺血再灌注对照组,ischemia control):缺血20 min,复灌时给予改良的K-H液灌注60 min;A3-A8组(缺血再灌注PSS给药组,ischemia control plus PSS 0.3,1,3,10,30 or 100):缺血20 min,复灌时给予含0.3,1,3,10,30,100 mg/L PSS的改良K-H液灌注60min。记录心脏收缩舒张功能指标,包括左心室发展峰压(left ventricular灌注developed pressure,LVDP)、左心室舒张末压(left ventricular end diastolic pressure,LVEDP)、左室内压最大上升及下降速率(maximum rate of intraventricular pressuredevelopment and relaxation;+dp/dt max,-dp/dt max)和心率(heart rate)。记录冠脉流量(coronary flow)。收集冠脉流出液,测定其中肌酸激酶(creatine kinase,CK)和乳酸脱氢酶(lactate dehydrogenase,LDH)含量。裂解心脏组织,测定心肌组织TNF-α蛋白含量及MAPK信号转导通路的关键性调控蛋白包括细胞外信号调节激酶(extracellular signal-regulated kinases,ERKs),c-Jun氨基末端激酶(c-junamino-terminal kinase,JNKs)和p38丝裂原活化蛋白激酶(p38 mitogen-activatedprotein kinase,p38 MAPK)的活性。
结果:
1～30 mg/L PSS可以提高缺血再灌注后心脏的LVDP%、+dp/dt max%、-dp/dtmax%和冠脉流量百分比,降低LVEDP%,对心率无明显影响。同时,1-30 mg/L PSS明显降低缺血再灌注后心脏释放的CK和LDH量,降低心肌组织升高的TNF-α水平及升高的p-p38MAPK和p-p54/p46-JNK蛋白表达水平。0.3 mg/L PSS对心脏舒缩功能和冠脉流量、心率、CK和LDH释放、TNF-α水平及p-p38MAPK和p-p54/p46-JNK水平均未产生影响。100 mg/L PSS则使本已受损的心功能进一步恶化,导致心脏舒缩功能、冠脉流量和心率的明显下降。0.3～100 mg/L PSS对P-p44/p42-ERK蛋白表达均为产生明显影响。
结论:
一定浓度的PSS(1～30mg/L)对于缺血再灌注损伤后的心脏,具有提高心脏舒缩功能,减轻心肌细胞损伤,提高冠脉流量而不改变心率等药理效应。该效应可能与减少缺血再灌注损伤所致的TNF-α表达水平的升高,逆转缺血再灌注损伤引起的MAPK通路改变相关。
Part 1 Beneficial effect of rosuvastatin on heart failure is associated with alterations of calcium-regulatory proteins
Background:
The release of Ca~(2+) from sarcoplasmic reticulum(SR) and sarcoplasmic Ca~(2+) reuptake mainly involve in the regulation of intracellular Ca~(2+) homeostasis and its pathophysiological change.Sarcoplasmic reticulum Ca~(2+) ATPase(SERCA) and SERCA regulatory protein phospholamban(PLB) are the key proteins responsible for maintaining Ca~(2+) homeostasis throughout the excitation-contraction coupling cycle in cardiomyocyte.Interfering with the abnormal expression of SERCA and PLB may be a promising method in the clinical treatment of HF patients.
Recent clinical and experimental studies indicated that statins(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) can attenuate ventricular remodeling and improve ventricular function after myocardial infarction(MI).But there are few data exploring whether statins exhibit special effect in improving left ventricular(LV) remodeling and function through influence on calcium-regulatory proteins.
Aim:
We undertook our research to investigate effect of rosuvastatin on LV remodeling and cardiac function in a rat model of HF induced by MI.In addition,tissue levels of SERCA2a,SERCA activity,PLB and pSerl6-PLB as well as interleukin(IL)-6 and IL-10 in myocardium of rats with MI were detected to explore the molecular mechanism.
Methods:
Adult male Sprague-Dawley rats were anesthetized and the left coronary artery was ligated 2 to 3 mm from its origin to induce MI.For sham-operated animals,the suture was placed but not ligated(S group).MI rats were randomized to receive gavage with either 1 ml·day-1 distilled water(MI group) or 10 mg·kg-1·day-1 rosuvastatin dissolved in 1 ml distilled water for 10 weeks(MI+R group).Normal control(NC group) and normal control plus rosuvastatin treatment rats(NC+R group) were randomly selected.Rats were evaluated by echocardiography 2,4,6,8 and 10 weeks after operation.Left ventricle(LV) internal diameter at end-diastolic phase(LVIDd),LV internal diameter at end-systolic phase(LVIDs),LV posterior wall thickness at diastolic phase(LVPWd),LV shortening fraction(FS) and ejection fraction(EF) were measured. Infarct size was also detected by echocardiography 2 and 10 weeks after MI.10 weeks after MI,rats were anesthetized,and hemodynamic variables were measured.After rats were sacrificed,LV relative weight(LVRW) and right ventricular relative weight (RVRW) were obtained,when the LV actual weight(LVAW) and right ventricular actual weight(RVAW) were corrected for body weight.Serum total cholesterol,triglycerides, and low- and high-density lipoprotein cholesterol were measured using enzymatic colorimetric assays.SR was prepared from LV tissue for Determination of SERCA activity.The protein expression of SERCA2a,PLB and phospho-PLB at serine-16 (pSer16-PLB) were detected by western blot.IL-6 and IL-10 levels were assessed by enzyme-linked immunosorbent assay.
Results:
After rosuvastatin treatment,LV remodeling and dysfunction were attenuated. Rosuvastatin partially restored the low expression of SERCA2a and pSerl6-PLB, increased SERCA activity,but showed no effect on PLB expression.Furthermore, rosuvastatin reduced the increased IL-6 level and further elevated IL-10 level in the peri-infarct and remote zones of MI.Serum lipid levels and infarct size remained unchanged.
Conlusions:
Rosuvastatin is effective in reducing LV remodeling and dysfunction in the failing heart.The molecular mechanism may be related to normalization of SERCA2a expression,SERCA activity,and pSerl6-PLB levels,as well as through cytokine alterations independent of its effect of lipid-lowering or MI size reduction.
Part 2 Cardioprotection and mechanisms of polysaccharide sulfate against ischemia/reperfusion injury in isolated rat hearts
Background:
Polysaccharide sulfate(PSS) is a new type heparinoid extracted from Phylum Phaeophyta.By chemically introducing sulfuryl and propylene glycol residues in the hydroxyl and carboxyl group of alginic acid sodium,PSS obtained is a diester sodium. Basic and clinical research showed PSS have the effect of anticoagulation,lowering blood viscosity,decreasing TC and TG,increasing HDL-C,depressing platelet release, stimulating PGI2 synthesis and improving microcirculation.Clinically,there is a sort of myocardial injury,which occurs with transient ischemia followed by re-establishment of flow,and results in prolonged postischemic contractile dysfunction of myocardium. Although PSS is successfully applied in ischemic cardio-cerebrovascular disease,its effect on cardiac function after ischemia/reperfusion(I/R) injury has not been investigated previously.
Aim:
The aim of the present study was to investigate whether acute application of PSS can protect the heart from I/R injury in a model of myocardial I/R of the isolated rat hearts.In addition,the present study is designed to explore whether the cardioprotective effect of PSS is based on the alterations of tumor necrosis factor-a(TNF-α) expression and mitogen-activated protein kinase(MAPK) signal transduction pathway.
Methods:
Isolated rat hearts were perfused(Langendorff) and subjected to 20 min global ischemia followed by 60 min reperfusion with Kreb's Henseleit solution or different concentrations of PSS(0.3～100 mg/L).Myocardial contractile and diastolic function (including left ventricular developed pressure,LVDP;left ventricular end diastolic pressure,LVEDP;maximum rate of intraventricular pressure development and relaxation,+dp/dt max and -dp/dt max) was continuously recorded.Heart rate and the coronary flow were measured.Creatinine kinase(CK) and lactate dehydrogenase(LDH) leakage were measured.Tumor necrosis factor-α(TNF-α) expression by cardiomyocytes was investigated.Western blot analysis for extracellular regulated kinases(ERKs),c-jun amino-terminal kinase(JNKs) and p38 mitogen-activated protein kinase(MAPK) activity were performed.
Results:
PSS administration at concentrations of 1-30 mg/L improved cardiac contractility, reduced CK and LDH releasing and inhibited TNF-αproduction.Phosphorylated-p38MAPK(p-p38MAPK) and p-p54/p46-JNK increased in I/R rat hearts but diminished in PSS(1～30 mg/L) treated hearts.0.3 mg/L PSS had no effect on cardiac contractility,CK and LDH releasing,TNF-αproduction as well as p-p38MAPK and p-p54/p46-JNK expression.In contrast,high concentration of PSS(100 mg/L) had adverse effects that caused worsening of heart function.P-p44/p42-ERK level was unchanged after 0.3～100 mg/L PSS treatment.
Conlusions:
PSS has cardioprotective effect against I/R injury on the rat heart dose-dependently. The beneficial pharmacological effect including improving cardiac performance, increasing coronary flow but not affecting heart rate and lowering cardiocyte injury may be mediated through normalization of p38 MAPK and JNK pathways as well as TNF-αexpression.
引文
[1]Periasamy M,Huke S.SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility.J Mol Cell Cardiol 2001;33:1053-63.
[2]Vangheluwe P,Raeymaekers L,Dode L,Wuytack F.Modulating sarco(endo) plasmic reticulum Ca2+ ATPase 2(SERCA2) activity:cell biological implications.Cell Calcium 2005;38:291-302.
[3]Gianni D,Chan J,Gwathmey JK,del Monte F,Hajjar RJ.SERCA2a in heart failure:role and therapeutic prospects.J Bioenerg Biomembr 2005;37:375-80.
[4]Piacentino V 3rd,Weber CR,Chen X,Weisser-Thomas J,Margulies KB,Bers DM,Houser SR.Cellular basis of abnormal calcium transients of failing human ventricular myocytes.Circ Res 2003;92:651-8.
[5]Hasenfuss G.Alterations of calcium-regulatory proteins in heart failure.Cardiovasc Res 1998;37:279-89.
[6]Ohara Y,Hiasa Y,Hosokawa S,Miyazaki S,Ogura R,Miyajima H,Yuba K,Suzuki N,Takahashi T,Kishi K,Ohtani R.Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty.Int Heart J 2005;46:987-95.
[7]Zheng X,Hu SJ.Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart.Acta Pharmacol Sin 2005;26:696-704.
[8]McTaggart F,Buckett L,Davidson R,Holdgate G,McCormick A,Schneck D,Smith G,Warwick M.Preclinical and clinical pharmacology of Rosuvastatin,a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.Am J Cardiol 2001;87:28B-32B.
[9]Jones SP,Gibson MF,Rimmer DM 3rd,Gibson TM,Sharp BR,Lefer DJ.Direct vascular and cardioprotective effects of rosuvastatin,a new HMG-CoA reductase inhibitor.J Am Coll Cardiol 2002;40:1172-8.
[10]Mann DL,McMurray JJ,Packer M,Swedberg K,Borer JS,Colucci WS,Djian J,Drexler H,Feldman A,Kober L,Krum H,Liu P,Nieminen M,Tavazzi L,van Veldhuisen DJ,Waldenstrom A,Warren M,Westheim A,Zannad F,Fleming T.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation(RENEWAL).Circulation 2004;109:1594-602.
[11]Anker SD,Coats AJ.How to RECOVER from RENAISSANCE?The significance of the results of RECOVER,RENAISSANCE,RENEWAL and ATTACH.Int J Cardiol 2002;86:123-30.
[12]Martin JH,Krum H.Statins and clinical outcomes in heart failure.Clin Sci(Lond) 2007;113:119-27.
[13]van der Harst P,Voors AA,van Gilst WH,Bohm M,van Veldhuisen DJ.Statins in the treatment of chronic heart failure:a systematic review.PLoS Med 2006;3:e333.
[14]Nakaya R,Uzui H,Shimizu H,Nakano A,Mitsuke Y,Yamazaki T,Ueda T,Lee JD.Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.Int J Cardiol 2005;105:67-73.
[15]Shanes JG,Minadeo KN,Moret A,Groner M,Tabaie SA.Statin therapy in heart failure:prognostic effects and potential mechanisms.Am Heart J 2007;154:617-23.
[16]Di Napoli P,Taccardi AA,Grilli A,De Lutiis MA,Barsotti A,Felaco M,De Caterina R.Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.Cardiovasc Res 2005;66:462-71.
[17]Sironi L,Gianazza E,Gelosa P,Guerrini U,Nobili E,Gianella A,Cremonesi B,Paoletti R,Tremoli E.Rosuvastatin,but not simvastatin,provides end-organ protection in stroke-prone rats by antiinflammatory effects.Arterioscler Thromb Vasc Biol 2005;25:598-603.
[18]Nicolosi GL.Cardiac remodeling and failure after myocardial infarction.J Cardiovasc Risk 1994;1:310-3.
[19]Endo A,Tsujita Y,Kuroda M,Tanzawa K.Effects of ML-236B on cholesterol metabolism in mice and rats:lack of hypocholesterolemic activity in normal animals.Biochim Biophys Acta 1979;575:266-76.
[20]Laufs U,Custodis F,Bohm M.HMG-CoA reductase inhibitors in chronic heart failure:potential mechanisms of benefit and risk.Drugs 2006;66:145-54.
[21]Takayama T,Wada A,Tsutamoto T,Ohnishi M,Fujii M,Isono T,Horie M.Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.Circ J 2004;68:1067-75.
[22]Schafer A,Fraccarollo D,Eigenthaler M,Tas P,Firnschild A,Frantz S,Ertl G,Bauersachs J.Rosuvastatin reduces platelet activation in heart failure:role of NO bioavailability.Arterioscler Thromb Vasc Biol 2005;25:1071-7.
[23]Tousoulis D,Charakida M,Stefanadi E,Siasos G,Latsios G,Stefanadis C.Statins in heart failure.Beyond the lipid lowering effect.Int J Cardiol 2007;115:144-50.
[24]Periasamy M,Kalyanasundaram A.SERCA pump isoforms:their role in calcium transport and disease.Muscle Nerve 2007;35:430-42.
[25]Muller OJ,Lange M,Rattunde H,Lorenzen HP,Muller M,Frey N,Bittner C,Simonides W,Katus HA,Franz WM.Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload.Cardiovasc Res 2003;59:380-9.
[26]Chakraborti S,Das S,Kar P,Ghosh B,Samanta K,Kolley S,Ghosh S,Roy S,Chakraborti T.Calcium signaling phenomena in heart diseases:a perspective.Mol Cell Biochem 2007;298:1-40.
[27]Schwinger RH,Munch G,Bolck B,Karczewski P,Krause EG,Erdmann E.Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation.J Mol Cell Cardiol 1999;31:479-91.
[28]Jiang MT,Lokuta AJ,Farrell EF,Wolff MR,Haworth RA,Valdivia HH.Abnormal Ca2+ release,but normal ryanodine receptors,in canine and human heart failure.Circ Res 2002;91:1015-22.
[29]Frank KF,Bolck B,Brixius K,Kranias EG,Schwinger RH.Modulation of SERCA:implications for the failing human heart.Basic Res Cardiol 2002;97 Suppl 1:172-8.
[30]Shao Q,Ren B,Saini HK,Netticadan T,Takeda N,Dhalla NS.Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.Am J Physiol Heart Circ Physiol 2005;288:H1674-82.
[31]Guo X,Chapman D,Dhalla NS.Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.Mol Cell Biochem 2003;254:163-72.
[32]Sjaastad I,Bokenes J,Swift F,Wasserstrom JA,Sejersted OM.Normal contractions triggered by I(Ca,L) in ventricular myocytes from rats with postinfarction CHF. Am J Physiol Heart Circ Physiol 2002;283:H1225-36.
[33]Linck B,Boknik P,Eschenhagen T,Muller FU,Neumann J,Nose M,Jones LR,Schmitz W,Scholz H.Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts.Cardiovasc Res 1996;31:625-32.
[34]Schwinger RH,Bohm M,Schmidt U,Karczewski P,Bavendiek U,Flesch M,Krause EG,Erdmann E.Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.Circulation 1995;92:3220-8.
[35]Flesch M,Schwinger RH,Schnabel P,Schiffer F,van Gelder I,Bavendiek U,Sudkamp M,Kuhn-Regnier F,Bohm M.Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy.J Mol Med 1996;74:321-32.
[36]Bohm M,Reiger B,Schwinger RH,Erdmann E.cAMP concentrations,cAMP dependent protein kinase activity,and phospholamban in non-failing and failing myocardium.Cardiovasc Res 1994;28:1713-9.
[37]Gupta D,Palma J,Molina E,Gaughan JP,Long W,Houser S,Macha M.Improved exercise capacity and reduced systemic inflammation after adenoviral-mediated SERCA-2a gene transfer.J Surg Res 2008;145:257-65.
[38]Byrne MJ,Power JM,Preovolos A,Mariani JA,Hajjar RJ,Kaye DM.Recirculating cardiac delivery of AAV2/lSERCA2a improves myocardial function in an experimental model of heart failure in large animals.Gene Ther 2008;15:1550-7.
[39]Dieterle T,Meyer M,Gu Y,Belke DD,Swanson E,Iwatate M,Hollander J,Peterson KL,Ross J Jr,Dillmann WH.Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure.Cardiovasc Res 2005;67:678-88.
[40]Ziolo MT,Martin JL,Bossuyt J,Bers DM,Pogwizd SM.Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function.Circ Res 2005;96:815-7.
[41]Zhao XY,Hu SJ,Li J,Mou Y,Bian K,Sun J,Zhu ZH.rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+-ATPase activity and cardiac dysfunction in rats with myocardial infarction.Eur J Heart Fail 2008;10:47-54.
[42]Maczewski M,Maczewska J,Duda M.Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat:role of angiotensin Ⅱ type 1 receptors.Br J Pharmacol 2008;154:1640-8.
[43]Kobayashi N,Takeshima H,Fukushima H,Koguchi W,Mamada Y,Hirata H,Machida Y,Shinoda M,Suzuki N,Yokotsuka F,Tabei K,Matsuoka H.Cardioprotective Effects of Pitavastatin on Cardiac Performance and Remodeling in Failing Rat Hearts.Am J Hypertens 2008.
[44]Elrod JW,Lefer DJ.The effects of statins on endothelium,inflammation and cardioprotection.Drug News Perspect JT-Drug news & perspectives 2005;18:229-36.
[45]Conraads V.Pro-inflammatory cytokines and their receptors in chronic heart failure:do they really matter?.Acta Cardiol 2006;61:161-8.
[46]White M,Ducharme A,Ibrahim R,Whittom L,Lavoie J,Guertin MC,Racine N,He Y,Yao G,Rouleau JL,Schiffrin EL,Touyz RM.Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure:improvement after short-term inotropic support.Clin Sci(Lond) 2006;110:483-9.
[47]Paulus WJ.Cytokines and heart failure.Heart Fail Monit 2000;1:50-6.
[48]Candia AM,Villacorta Junior H,Mesquita ET.[Immune-inflammatory activation in heart failure.].Arq Bras Cardiol 2007;89:201-8.
[49]Kaur K,Dhingra S,Slezak J,Sharma AK,Bajaj A,Singal PK.Biology of TNFalpha and IL-10,and their imbalance in heart failure.Heart Fail Rev 2008.
[50]Bolger AP,Sharma R,von Haehling S,Doehner W,Oliver B,Rauchhaus M,Coats AJ,Adcock IM,Anker SD.Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.Am J Cardiol 2002;90:384-9.
[51]Tanaka T,Kanda T,Takahashi T,Saegusa S,Moriya J,Kurabayashi M.Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes.J Int Med Res 2004;32:57-61.
[52]Villegas S,Villarreal FJ,Dillmann WH.Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase(SERCA2) in cardiac myocytes.Basic Res Cardiol 2000;95:47-54.
[53]Yu XW,Chen Q,Kennedy RH,Liu SJ.Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes.J Physiol 2005;566:327-40.
[54]Takemoto M,Liao JK.Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.Arterioscler Thromb Vasc Biol 2001;21:1712-9.
[1]Han ZY,Wang QA,Zeng GJ.Clinical and laboratory observations on polysaccharide sulphate(PSS) in 282 cases of ischemic cerebrovascular disease.Chin Med J(Engl),1991,104:562-6.
[2]You Y,Xie HJ,Zhang YF,Liu ZJ,Yang QD.Effect of the P-selectin expression on cerebral blood flow in rats with cerebral ischemia-reperfusion injury.J Apoplexy and Nervous Diseases,2005,22:155-157.
[3]Black SC,Gralinski MR,Friedrichs GS,Kilgore KS,Driscoll EM,Lucchesi BR.Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.Cardiovasc Res,1995,29:629-36.
[4]Gralinski MR,Driscoll EM,Friedrichs GS,DeNardis MR,Lucchesi BR.Reduction of myocardial necrosis after glycosaminoglycan administration:effects of a single intravenous administration of heparin or N-Acetylheparin 2 hours before regional ischemia and reperfusion.J Cardiovasc Pharmacol Ther,1996,1:219-228.
[5]Park JL,Kilgore KS,Naylor KB,Booth EA,Murphy KL,Lucchesi BR.N-Acetylheparin pretreatment reduces infarct size in the rabbit.Pharmacology,1999,58:120-31.
[6]Zhao MM,Li Z,Teng Z,Zhao JS,Yu XH,Watanabe Y,Zhao LM.Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model.Yao Xue Xue Bao,2007,42:488-91.
[7]Xie SQ,Du GJ,Ji BS,Lin HH,Xu QT,Hu XJ,Zhang GQ.Effect of polysaccharide sulfate on brain environment after focal cerebral ischemia reperfusion in rat and its promotion for growth of the chick embryonic dorsal root ganglion.Chinese Pharmaceutical Journal,2006,41:33-36.
[8]Wu K,Qian WM,Wu P.Therapeutic effects of intravenous polysaccharide sulfate in treatment of coronary heart disease.Chinese Journal of Clinical Pharmacology and Therapeutics,1996,1:31-33.
[9]Bogoyevitch MA,Gillespie-Brown J,Ketterman AJ,Fuller SJ,Ben-Levy R,Ashworth A,Marshall CJ,Sugden PH.Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart.p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion.Circ Res,1996,79:162-73.
[10]Maulik N,Yoshida T,Zu YL,Sato M,Banerjee A,Das DK.Ischemic preconditioning triggers tyrosine kinase signaling:a potential role for MAPKAP kinase 2.Am J Physiol,1998,275:H1857-64.
[11]Liao P,Wang SQ,Wang S,Zheng M,Zheng M,Zhang SJ,Cheng H,Wang Y,Xiao RP.p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes.Circ Res,2002,90:190-6.
[12]Wang M,Sankula R,Tsai BM,Meldrum KK,Turrentine M,March KL,Brown JW,Dinarello CA,Meldrum DR.P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression.Shock,2004,21:170-4.
[13]Lewis TS,Shapiro PS,Ahn NG.Signal transduction through MAP kinase cascades.Adv Cancer Res,1998,74:49-139.
[14]Kyriakis JM,Avruch J.Sounding the alarm:protein kinase cascades activated by stress and inflammation.J Biol Chem,1996,271:24313-6.
[15]Wang X,Martindale JL,Liu Y,Holbrook NJ.The cellular response to oxidative stress:influences of mitogen-activated protein kinase signalling pathways on cell survival.Biochem J,1998,333(Pt 2):291-300.
[16]Arumugam TV,Shiels IA,Woodruff TM,Granger DN,Taylor SM.The role of the complement system in ischemia-reperfusion injury.Shock,2004,21:401-9.
[17]Cain BS,Meldrum DR,Dinarello CA,Meng X,Joo KS,Banerjee A,Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function.Crit Care Med,1999,27:1309-18.
[18]Maass DL,White J,Horton JW.IL-lbeta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma.Shock,2002,18:360-6.
[19]Sakamoto A,Matsumura J,Mii S,Gotoh Y,Ogawa R.A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production.Shock,2004,22:76-81.
[20]Wright JG,Kerr JC,Valeri CR,Hobson RW 2nd.Heparin decreases ischemia-reperfusion injury in isolated canine gracilis model.Arch Surg,1988,123:470-2.
[21]Marshall CJ.Specificity of receptor tyrosine kinase signaling:transient versus sustained extracellular signal-regulated kinase activation.Cell,1995,80:179-85.
[22]Sugden PH,Bogoyevitch MA.Intracellular signalling through protein kinases in the heart.Cardiovasc Res,1995,30:478-92.
[23]Liao S,Porter D,Scott A,Newman G,Doetschman T,Schultz Jel J.The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2:the role of JNK signaling.J Mol Cell Cardiol,2007,42:106-20.
[24]Milano G,Morel S,Bonny C,Samaja M,von Segesser LK,Nicod P,Vassalli G.A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo.Am J Physiol Heart Circ Physiol,2007,292:H1828-35.
[25]Gao F,Yue TL,Shi DW,Christopher TA,Lopez BL,Ohlstein EH,Barone FC,Ma XL.p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.Cardiovasc Res.53(2).Netherlands,2002.414-22.
[26]Kapadia S,Lee J,Torre-Amione G,Birdsall HH,Ma TS,Mann DL.Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.J Clin Invest,1995,96:1042-52.
[27]Odeh M.Tumor necrosis factor-alpha as a myocardial depressant substance.Int J Cardiol,1993,42:231-8.
[28]Meldrum DR.Tumor necrosis factor in the heart.Am J Physiol,1998,274:R577-95.
[29]Gurevitch J,Frolkis I,Yuhas Y,Paz Y,Matsa M,Mohr R,Yakirevich V.Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion.J Am Coll Cardiol,1996,28:247-52.
[30]Stambe C,Atkins RC,Hill PA,Nikolic-Paterson DJ.Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis.Kidney Int,2003,64:2121-32.
[31]Paz Y,Frolkis I,Pevni D,Shapira I,Yuhas Y,Iaina A,Wollman Y,Chernichovski T,Nesher N,Locker C,Mohr R,Uretzky G.Effect of tumor necrosis factor-alpha on endothelial and inducible nitric oxide synthase messenger ribonucleic acid expression and nitric oxide synthesis in ischemic and nonischemic isolated rat heart.J Am Coll Cardiol,2003,42:1299-305.
[32]Liu S,Wang CB,Guo SB,Yan YJ.The primary approach to untoward reactions and rational application of polysaccharide sulphate.Chinese Journal of Marine Drugs,1992,11:17-19.
[1]Levine B,Kalman J,Mayer L,Fillit HM,Packer M.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med,1990,323:236-41.
[2]Springer TA.Traffic signals for lymphocyte recirculation and leukocyte emigration:the multistep paradigm.Cell,1994,76:301-14.
[3]Mann DL.Recent insights into the role of tumor necrosis factor in the failing heart.Heart Fail Rev,2001,6:71-80.
[4]Torre-Amione G,Kapadia S,Lee J,Durand JB,Bies RD,Young JB,Mann DL.Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart.Circulation,1996,93:704-11.
[5]Mehra VC,Ramgolam VS,Bender JR.Cytokines and cardiovascular disease.J Leukoc Biol,2005,78:805-18.
[6]Prabhu SD.Cytokine-induced modulation of cardiac function.Circ Res,2004,95:1140-53.
[7]Anker SD,von Haehling S.Inflammatory mediators in chronic heart failure:an overview.Heart,2004,90:464-70.
[8]Torre-Amione G.Immune activation in chronic heart failure.Am J Cardiol,2005,95:3C-8C,discussion 38C-40C.
[9]Mann DL.Inflammatory mediators and the failing heart:past,present,and the foreseeable future.Circ Res,2002,91:988-98.
[10]Piagnerelli M,Boudjeltia KZ,Vanhaeverbeek M,Vincent JL.Red blood cell rheology in sepsis.Intensive Care Med,2003,29:1052-61.
[11]Riedemann NC,Guo RF,Neff TA,Laudes IJ,Keller KA,Sarma VJ,Markiewski MM,Mastellos D,Strey CW,Pierson CL,Lambris JD,Zetoune FS,Ward PA.Increased C5a receptor expression in sepsis.J Clin Invest,2002,110:101-8.
[12]Huber-Lang MS,Younkin EM,Sarma JV,McGuire SR,Lu KT,Guo RF,Padgaonkar VA,Curnutte JT,Erickson R,Ward PA.Complement-induced impairment of innate immunity during sepsis.J Immunol,2002,169:3223-31.
[13]Testa M,Yeh M,Lee P,Fanelli R,Loperfido F,Berman JW,LeJemtel TH.Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.J Am Coll Cardiol,1996,28:964-71.
[14]Rauchhaus M,Doehner W,Francis DP,Davos C,Kemp M,Liebenthal C,Niebauer J,Hooper J,Volk HD,Coats AJ,Anker SD.Plasma cytokine parameters and mortality in patients with chronic heart failure.Circulation,2000,102:3060-7.
[15]Matsumori A,Yamada T,Suzuki H,Matoba Y,Sasayama S.Increased circulating cytokines in patients with myocarditis and cardiomyopathy.Br Heart J,1994,72:561-6.
[16]Oren H,Erbay AR,Balci M,Cehreli S.Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction:do they affect the outcome of patients?.Angiology,2007,58:45-54.
[17]Martinez Rosas M.[Cardiac remodeling and inflammation].Arch Cardiol Mex,2006,76 Suppl 4:S58-66.
[18]Moro C,Jouan MG,Rakotovao A,Toufektsian MC,Ormezzano O,Nagy N,Tosaki A,de Leiris J,Boucher F.Delayed expression of cytokines after reperfused myocardial infarction:possible trigger for cardiac dysfunction and ventricular remodeling.Am J Physiol Heart Circ Physiol,2007,293:H3014-9.
[19]Anker SD,Egerer KR,Volk HD,Kox WJ,Poole-Wilson PA,Coats AJ.Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.Am J Cardiol,1997,79:1426-30.
[20]Genth-Zotz S,von Haehling S,Bolger AP,Kalra PR,Wensel R,Coats AJ,Anker SD.Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.Am J Cardiol,2002,90:1226-30.
[21]Niebauer J,Volk HD,Kemp M,Dominguez M,Schumann RR,Rauchhaus M,Poole-Wilson PA,Coats AJ,Anker SD.Endotoxin and immune activation in chronic heart failure:a prospective cohort study.Lancet,1999,353:1838-42.
[22]Aukrust P,Gullestad L,Ueland T,Damas JK,Yndestad A.Inflammatory and anti-inflammatory cytokines in chronic heart failure:potential therapeutic implications.Ann Med,2005,37:74-85.
[23]Vasan RS,Sullivan LM,Roubenoff R,Dinarello CA,Harris T,Benjamin EJ,Sawyer DB,Levy D,Wilson PW,D'Agostino RB.Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction:the Framingham Heart Study.Circulation,2003,107:1486-91.
[24]Torre-Amione G,Kapadia S,Benedict C,Oral H,Young JB,Mann DL.Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the Studies of Left Ventricular Dysfunction(SOLVD).J Am Coll Cardiol,1996,27:1201-6.
[25]Bozkurt B,Kribbs SB,Clubb FJ Jr,Michael LH,Didenko VV,Hornsby PJ,Seta Y,Oral H,Spinale FG,Mann DL.Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.Circulation,1998,97:1382-91.
[26]Gullestad L,Aukrust P,Ueland T,Espevik T,Yee G,Vagelos R,Froland SS,Fowler M.Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure.J Am Coll Cardiol,1999,34:2061-7.
[27]Gurlek A,Kilickap M,Dincer I,Dandachi R,Tutkak H,Oral D.Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure.J Cardiovasc Risk,2001,8:279-82.
[28]Tsutamoto T,Wada A,Matsumoto T,Maeda K,Mabuchi N,Hayashi M,Tsutsui T,Ohnishi M,Sawaki M,Fujii M,Matsumoto T,Yamamoto T,Horie H,Sugimoto Y,Kinoshita M.Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.J Am Coll Cardiol,2001,37:2086-92.
[29]Thaik CM,Calderone A,Takahashi N,Colucci WS.Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes.J Clin Invest,1995,96:1093-9.
[30]Kubota T,McTiernan CF,Frye CS,Slawson SE,Lemster BH,Koretsky AP,Demetris AJ,Feldman AM.Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.Circ Res,1997,81:627-35.
[31]Seta Y,Shan K,Bozkurt B,Oral H,Mann DL.Basic mechanisms in heart failure:the cytokine hypothesis.J Card Fail,1996,2:243-9.
[32]Eddy LJ,Goeddel DV,Wong GH.Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury.Biochem Biophys Res Commun,1992,184:1056-9.
[33]Wong GH,Goeddel DV.Induction of manganous superoxide dismutase by tumor necrosis factor:possible protective mechanism.Science,1988,242:941-4.
[34]Nakano M,Knowlton AA,Yokoyama T,Lesslauer W,Mann DL.Tumor necrosis factor-alpha-induced expression of heat shock protein 72 in adult feline cardiac myocytes.Am J Physiol,1996,270:H1231-9.
[35]Plumier JC,Ross BM,Currie RW,Angelidis CE,Kazlaris H,Kollias G,Pagoulatos GN.Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery.J Clin Invest,1995,95:1854-60.
[36]Deswal A,Petersen NJ,Feldman AM,Young JB,White BG,Mann DL.Cytokines and cytokine receptors in advanced heart failure:an analysis of the cytokine database from the Vesnarinone trial(VEST).Circulation,2001,103:2055-9.
[37]Tracey KJ,Beutler B,Lowry SF,Merryweather J,Wolpe S,Milsark IW,Hariri RJ,Fahey TJ 3rd,Zentella A,Albert JD,et al.Shock and tissue injury induced by recombinant human cachectin.Science,1986,234:470-4.
[38]Natanson C,Eichenholz PW,Danner RL,Eichacker PQ,Hoffman WD,Kuo GC,Banks SM,MacVittie TJ,Parrillo JE.Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.J Exp Med,1989,169:823-32.
[39]Pagani FD,Baker LS,Hsi C,Knox M,Fink MP,Visner MS.Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.J Clin Invest,1992,90:389-98.
[40]Franco F,Thomas GD,Giroir B,Bryant D,Bullock MC,Chwialkowski MC,Victor RG,Peshock RM.Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.Circulation,1999,99:448-54.
[41]Meldrum DR.Tumor necrosis factor in the heart.Am J Physiol,1998,274:R577-95.
[42]Gulick T,Chung MK,Pieper SJ,Lange LG,Schreiner GF.Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness.Proc Natl Acad Sci U S A,1989,86:6753-7.
[43]Balligand JL,Ungureanu D,Kelly RA,Kobzik L,Pimental D,Michel T,Smith TW.Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium.J Clin Invest,1993,91:2314-9.
[44]Kinugawa K,Takahashi T,Kohmoto O,Yao A,Aoyagi T,Momomura S,Hirata Y,Serizawa T.Nitric oxide-mediated effects of interleukin-6 on[Ca2+]i and cell contraction in cultured chick ventricular myocytes.Circ Res,1994,75:285-95.
[45]Hosenpud JD,Campbell SM,Mendelson DJ.Interleukin-1-induced myocardial depression in an isolated beating heart preparation.J Heart Transplant,1989,8:460-4.
[46]Finkel MS,Oddis CV,Jacob TD,Watkins SC,Hattler BG,Simmons RL.Negative inotropic effects of cytokines on the heart mediated by nitric oxide.Science,1992,257:387-9.
[47]Panas D,Khadour FH,Szabo C,Schulz R.Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism.Am J Physiol,1998,275:H1016-23.
[48]Kumar A,Brar R,Wang P,Dee L,Skorupa G,Khadour F,Schulz R,Parrillo JE.Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility.Am J Physiol,1999,276:R265-76.
[49]Dinarello CA.Interleukin-18.Methods,1999,19:121-32.
[50]Pomerantz BJ,Reznikov LL,Harken AH,Dinarello CA.Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-lbeta.Proc Natl Acad Sci U S A,2001,98:2871-6.
[51]Yokoyama T,Nakano M,Bednarczyk JL,Mclntyre BW,Entman M,Mann DL.Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes.Circulation,1997,95:1247-52.
[52]Krown KA,Page MT,Nguyen C,Zechner D,Gutierrez V,Comstock KL,Glembotski CC,Quintana PJ,Sabbadini RA.Tumor necrosis factor alphainduced apoptosis in cardiac myocytes.Involvement of the sphingolipid signaling cascade in cardiac cell death.J Clin Invest,1996,98:2854-65.
[53]Bryant D,Becker L,Richardson J,Shelton J,Franco F,Peshock R,Thompson M, Giroir B.Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.Circulation,1998,97:1375-81.
[54]Sivasubramanian N,Coker ML,Kurrelmeyer KM,MacLellan WR,DeMayo FJ,Spinale FG,Mann DL.Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.Circulation,2001,104:826-31.
[55]Li YY,Feng YQ,Kadokami T,McTiernan CF,Draviam R,Watkins SC,Feldman AM.Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.Proc Natl Acad Sci U S A,2000,97:12746-51.
[56]Weber KT.Cardiac interstitium in health and disease:the fibrillar collagen network.J Am Coll Cardiol,1989,13:1637-52.
[57]Knittel T,Mehde M,Grundmann A,Saile B,Scharf JG,Ramadori G.Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.Histochem Cell Biol,2000,113:443-53.
[58]Sime PJ,Marr RA,Gauldie D,Xing Z,Hewlett BR,Graham FL,Gauldie J.Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-betal and myofibroblasts.Am J Pathol,1998,153:825-32.
[59]Agnoletti L,Curello S,Bachetti T,Malacarne F,Gaia G,Comini L,Volterrani M,Bonetti P,Parrinello G,Cadei M,Grigolato PG,Ferrari R.Serum from patients with severe heart failure downregulates eNOS and is proapoptotic:role of tumor necrosis factor-alpha.Circulation,1999,100:1983-91.
[60]Anker SD,Volterrani M,Egerer KR,Felton CV,Kox WJ,Poole-Wilson PA,Coats AJ.Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure.QJM,1998,91:199-203.
[61]Fichtlscherer S,Rossig L,Breuer S,Vasa M,Dimmeler S,Zeiher AM.Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.Circulation,2001,104:3023-5.
[62]Kapadia S,Lee J,Torre-Amione G,Birdsall HH,Ma TS,Mann DL.Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.J Clin Invest,1995,96:1042-52.
[63]Torre-Amione G,Kapadia S,Lee J,Bies RD,Lebovitz R,Mann DL.Expression and functional significance of tumor necrosis factor receptors in human myocardium.Circulation,1995,92:1487-93.
[64]Bolger AP,Anker SD.Tumour necrosis factor in chronic heart failure:a peripheral view on pathogenesis,clinical manifestations and therapeutic implications.Drugs,2000,60:1245-57.
[65]von Haehling S,Jankowska EA,Anker SD.Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications.Basic Res Cardiol,2004,99:18-28.
[66]Torre-Amione G,Bozkurt B,Deswal A,Mann DL.An overview of tumor necrosis factor alpha and the failing human heart.Curr Opin Cardiol,1999,14:206-10.
[67]Feldman AM,Combes A,Wagner D,Kadakomi T,Kubota T,Li YY,McTiernan C.The role of tumor necrosis factor in the pathophysiology of heart failure.J Am Coll Cardiol,2000,35:537-44.
[68]Dinarello CA,Cannon JG,Wolff SM,Bernheim HA,Beutler B,Cerami A,Figari IS,Palladino MA Jr,O'Connor JV.Tumor necrosis factor(cachectin) is an endogenous pyrogen and induces production of interleukin 1.J Exp Med,1986,163:1433-50.
[69]Nakano M,Knowlton AA,Dibbs Z,Mann DL.Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation,1998,97:1392-400.
[70]Nagueh SF,Stetson SJ,Lakkis NM,Killip D,Perez-Verdia A,Entman ML,Spencer WH 3rd,Torre-Amione G.Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy.Circulation,2001,103:1844-50.
[71]Kapadia SR,Yakoob K,Nader S,Thomas JD,Mann DL,Griffin BP.Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload.J Am Coll Cardiol,2000,36:208-12.
[72]Sacher RA.Intravenous immunoglobulin consensus statement.J Allergy Clin Immunol,2001,108:S139-46.
[73]Murray DR,Freeman GL.Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs.Circ Res,1996,78:154-60.
[74]Dibbs Z,Thornby J,White BG,Mann DL.Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure:implications for clinical trials.J Am Coll Cardiol,1999,33:1935-42.
[75]Kapadia S,Torre-Amione G,Mann DL.Pitfalls in measuring cytokines.Ann Intern Med,1994,121:149-50.
[76]Kumar A,Haery C,Parrillo JE.Myocardial dysfunction in septic shock.Crit Care Clin,2000,16:251-87.
[77]Parrillo JE,Burch C,Shelhamer JH,Parker MM,Natanson C,Schuette W.A circulating myocardial depressant substance in humans with septic shock.Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.J Clin Invest,1985,76:1539-53.
[78]Kumar A,Wood K,Parrillo JE.Circulating substances and energy metabolism in septic shock.Crit Care Med,2003,31:632-3.
[79]Cain BS,Meldrum DR,Dinarello CA,Meng X,Joo KS,Banerjee A,Harken AH.Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function.Crit Care Med,1999,27:1309-18.
[80]El-Menyar AA.The resuscitation outcome:revisit the story of the stony heart.Chest,2005,128:2835-46.
[81]El-Menyar AA.Pathophysiology and hemodynamic of postresuscitation syndrome.Saudi Med J,2006,27:441-5.
[82]Sharma HS,Das DK.Role of cytokines in myocardial ischemia and reperfusion.Mediators Inflamm,1997,6:175-83.
[83]Niemann JT,Garner D,Lewis RJ.Tumor necrosis factor-alpha is associated with early postresuscitation myocardial dysfunction.Crit Care Med,2004,32:1753-8.
[84]van Deventer SJ,Buller HR,ten Cate JW,Aarden LA,Hack CE,Sturk A.Experimental endotoxemia in humans:analysis of cytokine release and coagulation,fibrinolytic,and complement pathways.Blood,1990,76:2520-6.
[85]Ng SB,Tan YH,Guy GR.Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.J Biol Chem,1994,269:19021-7.
[86]Sanceau J,Kaisho T,Hirano T,Wietzerbin J.Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1,NF kappa B,and Sp1 transcription factors.J Biol Chem,1995,270:27920-31.
[87]Baumann H,Gauldie J.Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation.Mol Biol Med,1990,7:147-59.
[88]Heinrich PC,Castell JV,Andus T.Interleukin-6 and the acute phase response.Biochem J,1990,265:621-36.
[89]Tsutamoto T,Hisanaga T,Wada A,Maeda K,Ohnishi M,Fukai D,Mabuchi N,Sawaki M,Kinoshita M.Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure,and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.J Am Coll Cardiol,1998,31:391-8.
[90]Mohler ER 3rd,Sorensen LC,Ghali JK,Schocken DD,Willis PW,Bowers JA,Cropp AB,Pressler ML.Role of cytokines in the mechanism of action of amlodipine:the PRAISE Heart Failure Trial.Prospective Randomized Amlodipine Survival Evaluation.J Am Coll Cardiol,1997,30:35-41.
[91]Sugishita K,Kinugawa K,Shimizu T,Harada K,Matsui H,Takahashi T,Serizawa T,Kohmoto O.Cellular basis for the acute inhibitory effects of IL-6 and TNF-alpha on excitation-contraction coupling.J Mol Cell Cardiol,1999,31:1457-67.
[92]Maeda K,Tsutamoto T,Wada A,Mabuchi N,Hayashi M,Tsutsui T,Ohnishi M,Sawaki M,Fujii M,Matsumoto T,Kinoshita M.High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.J Am Coll Cardiol,2000,36:1587-93.
[93]Bolger AP,Sharma R,von Haehling S,Doehner W,Oliver B,Rauchhaus M,Coats AJ,Adcock IM,Anker SD.Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.Am J Cardiol,2002,90:384-9.
[94]Nishio R,Matsumori A,Shioi T,Ishida H,Sasayama S.Treatment of experimental viral myocarditis with interleukin-10.Circulation,1999,100:1102-8.
[95]Gullestad L,Aass H,Fjeld JG,Wikeby L,Andreassen AK,Ihlen H,Simonsen S,Kjekshus J,Nitter-Hauge S,Ueland T,Lien E,Froland SS,Aukrust P.Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.Circulation,2001,103:220-5.
[96]Kaur K,Sharma AK,Singal PK.Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction.Am J Physiol Heart Circ Physiol,2006,291:H106-13.
[97]Nishii M,Inomata T,Takehana H,Takeuchi I,Nakano H,Koitabashi T,Nakahata J,Aoyama N,Izumi T.Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis.J Am Coll Cardiol,2004,44:1292-7.
[98]Kaneko K,Kanda T,Yamauchi Y,Hasegawa A,Iwasaki T,Arai M,Suzuki T,Kobayashi I,Nagai R.C-Reactive protein in dilated cardiomyopathy.Cardiology,1999,91:215-9.
[99]Anand IS,Latini R,Florea VG,Kuskowski MA,Rector T,Masson S,Signorini S,Mocarelli P,Hester A,Glazer R,Cohn JN.C-reactive protein in heart failure:prognostic value and the effect of valsartan.Circulation,2005,112:1428-34.
[100]Grabellus F,Levkau B,Sokoll A,Welp H,Schmid C,Deng MC,Takeda A,Breithardt G,Baba HA.Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support.Cardiovasc Res,2002,53:124-30.
[101]Tsutamoto T,Hisanaga T,Fukai D,Wada A,Maeda Y,Maeda K,Kinoshita M.Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure.Am J Cardiol,1995,76:803-8.
[102]Andreassen AK,Nordoy I,Simonsen S,Ueland T,Muller F,Froland SS,Gullestad L,Aukrust P.Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation.Am J Cardiol,1998,81:604-8.
[103]Devaux B,Scholz D,Hirche A,Klovekorn WP,Schaper J.Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure.Eur Heart J,1997,18:470-9.
[104]Drexler H,Hornig B.Endothelial dysfunction in human disease.J Mol Cell Cardiol,1999,31:51-60.
[105]Satoh M,Nakamura M,Tamura G,Makita S,Segawa I,Tashiro A,Satodate R,Hiramori K.Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy.J Am Coll Cardiol,1997,29:716-24.
[106]Heymes C,Vanderheyden M,Bronzwaer JG,Shah AM,Paulus WJ.Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy.Circulation,1999,99:3009-16.
[107]Doing A,Griffin D,Jacobson JA,Amber IJ,Gilbert E.B-cell function in chronic heart failure:antibody response to pneumococcal vaccine.J Card Fail,2001,7:318-21.
[108]Sliwa K,Skudicky D,Candy G,Wisenbaugh T,Sareli P.Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.Lancet,1998,351:1091-3.
[109]Deswal A,Bozkurt B,Seta Y,Parilti-Eiswirth S,Hayes FA,Blosch C,Mann DL.Safety and efficacy of a soluble P75 tumor necrosis factor receptor(Enbrel,etanercept) in patients with advanced heart failure.Circulation,1999,99:3224-6.
[110]Bozkurt B,Torre-Amione G,Warren MS,Whitmore J,Soran OZ,Feldman AM,Mann DL.Results of targeted anti-tumor necrosis factor therapy with etanercept(ENBREL) in patients with advanced heart failure.Circulation,2001,103:1044-7.
[111]Mann DL,McMurray JJ,Packer M,Swedberg K,Borer JS,Colucci WS,Djian J,Drexler H,Feldman A,Kober L,Krum H,Liu P,Nieminen M,Tavazzi L,van Veldhuisen DJ,Waldenstrom A,Warren M,Westheim A,Zannad F,Fleming T.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation(RENEWAL).Circulation,2004,109:1594-602.
[112]Anker SD,Coats AJ.How to RECOVER from RENAISSANCE?The significance of the results of RECOVER,RENAISSANCE,RENEWAL and ATTACH.Int J Cardiol,2002,86:123-30.
[113]Chung ES,Packer M,Lo KH,Fasanmade AA,Willerson JT.Randomized,double-blind,placebo-controlled,pilot trial of infliximab,a chimeric monoclonal antibody to tumor necrosis factor-alpha,in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure(ATTACH) trial.Circulation,2003,107:3133-40.
[114]Samuelsson A,Towers TL,Ravetch JV.Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.Science,2001,291:484-6.
[115]McNamara DM,Holubkov R,Starling RC,Dec GW,Loh E,Torre-Amione G,Gass A,Janosko K,Tokarczyk T,Kessler P,Mann DL,Feldman AM.Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.Circulation,2001,103:2254-9.
[116]Fadok VA,Bratton DL,Konowal A,Freed PW,Westcott JY,Henson PM.Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta,PGE2,and PAF.J Clin Invest,1998,101:890-8.
[117]Voll RE,Herrmann M,Roth EA,Stach C,Kalden JR,Girkontaite I.Immunosuppressive effects of apoptotic cells.Nature,1997,390:350-1.
[118]Babaei S,Stewart DJ,Picard P,Monge JC.Effects of VasoCare therapy on the initiation and progression of atherosclerosis.Atherosclerosis,2002,162:45-53.
[119]Torre-Amione G,Sestier F,Radovancevic B,Young J.Effects of a novel immune modulation therapy in patients with advanced chronic heart failure:results of a randomized,controlled,phase Ⅱ trial.J Am Coll Cardiol,2004,44:1181-6.
[120]Torre-Amione G,Bourge RC,Colucci WS,Greenberg B,Pratt C,Rouleau JL, Sestier F,Moye LA,Geddes JA,Nemet AJ,Young JB.A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure:the ACCLAIM trial rationale and design.Can J Cardiol,2007,23:369-76.
[121]Muller J,Wallukat G,Dandel M,Bieda H,Brandes K,Spiegelsberger S,Nissen E,Kunze R,Hetzer R.Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.Circulation,2000,101:385-91.
[122]von Haehling S,Anker SD,Bassenge E.Statins and the role of nitric oxide in chronic heart failure.Heart Fail Rev,2003,8:99-106.
[123]Hernandez-Perera O,Perez-Sala D,Navarro-Antolin J,Sanchez-Pascuala R,Hernandez G,Diaz C,Lamas S.Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,atorvastatin and simvastatin,on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.J Clin Invest,1998,101:2711-9.
[124]Laufs U,La Fata V,Plutzky J,Liao JK.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.Circulation,1998,97:1129-35.
[125]Node K,Fujita M,Kitakaze M,Hori M,Liao JK.Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy.Circulation,2003,108:839-43.
[126]Rauchhaus M,Coats AJ,Anker SD.The endotoxin-lipoprotein hypothesis.Lancet,2000,356:930-3.
[127]Tousoulis D,Antoniades C,Bosinakou E,Kotsopoulou M,Pitsavos C,Vlachopoulos C,Panagiotakos D,Stefanadis C.Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.Atherosclerosis,2005,178:359-63.
[128]Tousoulis D,Antoniades C,Bosinakou E,Kotsopoulou M,Tsioufis C,Tentolouris C,Trikas A,Pitsavos C,Stefanadis C.Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.Heart,2005,91:27-31.
[129]Strey CH,Young JM,Molyneux SL,George PM,Florkowski CM,Scott RS,Frampton CM.Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.Atherosclerosis,2005,179:201-6.
[130]Angermann CE,Nitschmann S.[Statin therapy for systolic heart failure.The CORONA trial(Controlled Rosuvastatin Multinational Trial in Heart Failure).].Internist(Berl) 2008.
[131]Tavazzi L,Tognoni G,Franzosi MG,Latini R,Maggioni AP,Marchioli R,Nicolosi GL,Porcu M.Rationale and design of the GISSI heart failure trial:a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.Eur J Heart Fail,2004,6:635-41.
[132]Kjekshus J,Dunselman P,Blideskog M,Eskilson C,Hjalmarson A,McMurray JV,Waagstein F,Wedel H,Wessman P,Wikstrand J.A statin in the treatment of heart failure?Controlled rosuvastatin multinational study in heart failure(CORONA):study design and baseline characteristics.Eur J Heart Fail,2005,7:1059-69.
[133]Fonarow GC.Randomized clinical outcome trials of statins in heart failure.Heart Fail Clin,2008,4:225-9.
[134]Gissi-HF Investigators,Tavazzi L,Maggioni AP,Marchioli R,Barlera S,Franzosi MG,Latini R,Lucci D,Nicolosi GL,Porcu M,Tognoni G.Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial):a randomised,double-blind,placebo-controlled trial.Lancet,2008,372:1231-9.
[2]Vangheluwe P,Raeymaekers L,Dode L,Wuytack F.Modulating sarco(endo) plasmic reticulum Ca2+ ATPase 2(SERCA2) activity:cell biological implications.Cell Calcium 2005;38:291-302.
[3]Gianni D,Chan J,Gwathmey JK,del Monte F,Hajjar RJ.SERCA2a in heart failure:role and therapeutic prospects.J Bioenerg Biomembr 2005;37:375-80.
[4]Piacentino V 3rd,Weber CR,Chen X,Weisser-Thomas J,Margulies KB,Bers DM,Houser SR.Cellular basis of abnormal calcium transients of failing human ventricular myocytes.Circ Res 2003;92:651-8.
[5]Hasenfuss G.Alterations of calcium-regulatory proteins in heart failure.Cardiovasc Res 1998;37:279-89.
[6]Ohara Y,Hiasa Y,Hosokawa S,Miyazaki S,Ogura R,Miyajima H,Yuba K,Suzuki N,Takahashi T,Kishi K,Ohtani R.Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty.Int Heart J 2005;46:987-95.
[7]Zheng X,Hu SJ.Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart.Acta Pharmacol Sin 2005;26:696-704.
[8]McTaggart F,Buckett L,Davidson R,Holdgate G,McCormick A,Schneck D,Smith G,Warwick M.Preclinical and clinical pharmacology of Rosuvastatin,a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.Am J Cardiol 2001;87:28B-32B.
[9]Jones SP,Gibson MF,Rimmer DM 3rd,Gibson TM,Sharp BR,Lefer DJ.Direct vascular and cardioprotective effects of rosuvastatin,a new HMG-CoA reductase inhibitor.J Am Coll Cardiol 2002;40:1172-8.
[10]Mann DL,McMurray JJ,Packer M,Swedberg K,Borer JS,Colucci WS,Djian J,Drexler H,Feldman A,Kober L,Krum H,Liu P,Nieminen M,Tavazzi L,van Veldhuisen DJ,Waldenstrom A,Warren M,Westheim A,Zannad F,Fleming T.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation(RENEWAL).Circulation 2004;109:1594-602.
[11]Anker SD,Coats AJ.How to RECOVER from RENAISSANCE?The significance of the results of RECOVER,RENAISSANCE,RENEWAL and ATTACH.Int J Cardiol 2002;86:123-30.
[12]Martin JH,Krum H.Statins and clinical outcomes in heart failure.Clin Sci(Lond) 2007;113:119-27.
[13]van der Harst P,Voors AA,van Gilst WH,Bohm M,van Veldhuisen DJ.Statins in the treatment of chronic heart failure:a systematic review.PLoS Med 2006;3:e333.
[14]Nakaya R,Uzui H,Shimizu H,Nakano A,Mitsuke Y,Yamazaki T,Ueda T,Lee JD.Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.Int J Cardiol 2005;105:67-73.
[15]Shanes JG,Minadeo KN,Moret A,Groner M,Tabaie SA.Statin therapy in heart failure:prognostic effects and potential mechanisms.Am Heart J 2007;154:617-23.
[16]Di Napoli P,Taccardi AA,Grilli A,De Lutiis MA,Barsotti A,Felaco M,De Caterina R.Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.Cardiovasc Res 2005;66:462-71.
[17]Sironi L,Gianazza E,Gelosa P,Guerrini U,Nobili E,Gianella A,Cremonesi B,Paoletti R,Tremoli E.Rosuvastatin,but not simvastatin,provides end-organ protection in stroke-prone rats by antiinflammatory effects.Arterioscler Thromb Vasc Biol 2005;25:598-603.
[18]Nicolosi GL.Cardiac remodeling and failure after myocardial infarction.J Cardiovasc Risk 1994;1:310-3.
[19]Endo A,Tsujita Y,Kuroda M,Tanzawa K.Effects of ML-236B on cholesterol metabolism in mice and rats:lack of hypocholesterolemic activity in normal animals.Biochim Biophys Acta 1979;575:266-76.
[20]Laufs U,Custodis F,Bohm M.HMG-CoA reductase inhibitors in chronic heart failure:potential mechanisms of benefit and risk.Drugs 2006;66:145-54.
[21]Takayama T,Wada A,Tsutamoto T,Ohnishi M,Fujii M,Isono T,Horie M.Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.Circ J 2004;68:1067-75.
[22]Schafer A,Fraccarollo D,Eigenthaler M,Tas P,Firnschild A,Frantz S,Ertl G,Bauersachs J.Rosuvastatin reduces platelet activation in heart failure:role of NO bioavailability.Arterioscler Thromb Vasc Biol 2005;25:1071-7.
[23]Tousoulis D,Charakida M,Stefanadi E,Siasos G,Latsios G,Stefanadis C.Statins in heart failure.Beyond the lipid lowering effect.Int J Cardiol 2007;115:144-50.
[24]Periasamy M,Kalyanasundaram A.SERCA pump isoforms:their role in calcium transport and disease.Muscle Nerve 2007;35:430-42.
[25]Muller OJ,Lange M,Rattunde H,Lorenzen HP,Muller M,Frey N,Bittner C,Simonides W,Katus HA,Franz WM.Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload.Cardiovasc Res 2003;59:380-9.
[26]Chakraborti S,Das S,Kar P,Ghosh B,Samanta K,Kolley S,Ghosh S,Roy S,Chakraborti T.Calcium signaling phenomena in heart diseases:a perspective.Mol Cell Biochem 2007;298:1-40.
[27]Schwinger RH,Munch G,Bolck B,Karczewski P,Krause EG,Erdmann E.Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation.J Mol Cell Cardiol 1999;31:479-91.
[28]Jiang MT,Lokuta AJ,Farrell EF,Wolff MR,Haworth RA,Valdivia HH.Abnormal Ca2+ release,but normal ryanodine receptors,in canine and human heart failure.Circ Res 2002;91:1015-22.
[29]Frank KF,Bolck B,Brixius K,Kranias EG,Schwinger RH.Modulation of SERCA:implications for the failing human heart.Basic Res Cardiol 2002;97 Suppl 1:172-8.
[30]Shao Q,Ren B,Saini HK,Netticadan T,Takeda N,Dhalla NS.Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.Am J Physiol Heart Circ Physiol 2005;288:H1674-82.
[31]Guo X,Chapman D,Dhalla NS.Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.Mol Cell Biochem 2003;254:163-72.
[32]Sjaastad I,Bokenes J,Swift F,Wasserstrom JA,Sejersted OM.Normal contractions triggered by I(Ca,L) in ventricular myocytes from rats with postinfarction CHF. Am J Physiol Heart Circ Physiol 2002;283:H1225-36.
[33]Linck B,Boknik P,Eschenhagen T,Muller FU,Neumann J,Nose M,Jones LR,Schmitz W,Scholz H.Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts.Cardiovasc Res 1996;31:625-32.
[34]Schwinger RH,Bohm M,Schmidt U,Karczewski P,Bavendiek U,Flesch M,Krause EG,Erdmann E.Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.Circulation 1995;92:3220-8.
[35]Flesch M,Schwinger RH,Schnabel P,Schiffer F,van Gelder I,Bavendiek U,Sudkamp M,Kuhn-Regnier F,Bohm M.Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy.J Mol Med 1996;74:321-32.
[36]Bohm M,Reiger B,Schwinger RH,Erdmann E.cAMP concentrations,cAMP dependent protein kinase activity,and phospholamban in non-failing and failing myocardium.Cardiovasc Res 1994;28:1713-9.
[37]Gupta D,Palma J,Molina E,Gaughan JP,Long W,Houser S,Macha M.Improved exercise capacity and reduced systemic inflammation after adenoviral-mediated SERCA-2a gene transfer.J Surg Res 2008;145:257-65.
[38]Byrne MJ,Power JM,Preovolos A,Mariani JA,Hajjar RJ,Kaye DM.Recirculating cardiac delivery of AAV2/lSERCA2a improves myocardial function in an experimental model of heart failure in large animals.Gene Ther 2008;15:1550-7.
[39]Dieterle T,Meyer M,Gu Y,Belke DD,Swanson E,Iwatate M,Hollander J,Peterson KL,Ross J Jr,Dillmann WH.Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure.Cardiovasc Res 2005;67:678-88.
[40]Ziolo MT,Martin JL,Bossuyt J,Bers DM,Pogwizd SM.Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function.Circ Res 2005;96:815-7.
[41]Zhao XY,Hu SJ,Li J,Mou Y,Bian K,Sun J,Zhu ZH.rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+-ATPase activity and cardiac dysfunction in rats with myocardial infarction.Eur J Heart Fail 2008;10:47-54.
[42]Maczewski M,Maczewska J,Duda M.Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat:role of angiotensin Ⅱ type 1 receptors.Br J Pharmacol 2008;154:1640-8.
[43]Kobayashi N,Takeshima H,Fukushima H,Koguchi W,Mamada Y,Hirata H,Machida Y,Shinoda M,Suzuki N,Yokotsuka F,Tabei K,Matsuoka H.Cardioprotective Effects of Pitavastatin on Cardiac Performance and Remodeling in Failing Rat Hearts.Am J Hypertens 2008.
[44]Elrod JW,Lefer DJ.The effects of statins on endothelium,inflammation and cardioprotection.Drug News Perspect JT-Drug news & perspectives 2005;18:229-36.
[45]Conraads V.Pro-inflammatory cytokines and their receptors in chronic heart failure:do they really matter?.Acta Cardiol 2006;61:161-8.
[46]White M,Ducharme A,Ibrahim R,Whittom L,Lavoie J,Guertin MC,Racine N,He Y,Yao G,Rouleau JL,Schiffrin EL,Touyz RM.Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure:improvement after short-term inotropic support.Clin Sci(Lond) 2006;110:483-9.
[47]Paulus WJ.Cytokines and heart failure.Heart Fail Monit 2000;1:50-6.
[48]Candia AM,Villacorta Junior H,Mesquita ET.[Immune-inflammatory activation in heart failure.].Arq Bras Cardiol 2007;89:201-8.
[49]Kaur K,Dhingra S,Slezak J,Sharma AK,Bajaj A,Singal PK.Biology of TNFalpha and IL-10,and their imbalance in heart failure.Heart Fail Rev 2008.
[50]Bolger AP,Sharma R,von Haehling S,Doehner W,Oliver B,Rauchhaus M,Coats AJ,Adcock IM,Anker SD.Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.Am J Cardiol 2002;90:384-9.
[51]Tanaka T,Kanda T,Takahashi T,Saegusa S,Moriya J,Kurabayashi M.Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes.J Int Med Res 2004;32:57-61.
[52]Villegas S,Villarreal FJ,Dillmann WH.Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase(SERCA2) in cardiac myocytes.Basic Res Cardiol 2000;95:47-54.
[53]Yu XW,Chen Q,Kennedy RH,Liu SJ.Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes.J Physiol 2005;566:327-40.
[54]Takemoto M,Liao JK.Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.Arterioscler Thromb Vasc Biol 2001;21:1712-9.
[1]Han ZY,Wang QA,Zeng GJ.Clinical and laboratory observations on polysaccharide sulphate(PSS) in 282 cases of ischemic cerebrovascular disease.Chin Med J(Engl),1991,104:562-6.
[2]You Y,Xie HJ,Zhang YF,Liu ZJ,Yang QD.Effect of the P-selectin expression on cerebral blood flow in rats with cerebral ischemia-reperfusion injury.J Apoplexy and Nervous Diseases,2005,22:155-157.
[3]Black SC,Gralinski MR,Friedrichs GS,Kilgore KS,Driscoll EM,Lucchesi BR.Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.Cardiovasc Res,1995,29:629-36.
[4]Gralinski MR,Driscoll EM,Friedrichs GS,DeNardis MR,Lucchesi BR.Reduction of myocardial necrosis after glycosaminoglycan administration:effects of a single intravenous administration of heparin or N-Acetylheparin 2 hours before regional ischemia and reperfusion.J Cardiovasc Pharmacol Ther,1996,1:219-228.
[5]Park JL,Kilgore KS,Naylor KB,Booth EA,Murphy KL,Lucchesi BR.N-Acetylheparin pretreatment reduces infarct size in the rabbit.Pharmacology,1999,58:120-31.
[6]Zhao MM,Li Z,Teng Z,Zhao JS,Yu XH,Watanabe Y,Zhao LM.Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model.Yao Xue Xue Bao,2007,42:488-91.
[7]Xie SQ,Du GJ,Ji BS,Lin HH,Xu QT,Hu XJ,Zhang GQ.Effect of polysaccharide sulfate on brain environment after focal cerebral ischemia reperfusion in rat and its promotion for growth of the chick embryonic dorsal root ganglion.Chinese Pharmaceutical Journal,2006,41:33-36.
[8]Wu K,Qian WM,Wu P.Therapeutic effects of intravenous polysaccharide sulfate in treatment of coronary heart disease.Chinese Journal of Clinical Pharmacology and Therapeutics,1996,1:31-33.
[9]Bogoyevitch MA,Gillespie-Brown J,Ketterman AJ,Fuller SJ,Ben-Levy R,Ashworth A,Marshall CJ,Sugden PH.Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart.p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion.Circ Res,1996,79:162-73.
[10]Maulik N,Yoshida T,Zu YL,Sato M,Banerjee A,Das DK.Ischemic preconditioning triggers tyrosine kinase signaling:a potential role for MAPKAP kinase 2.Am J Physiol,1998,275:H1857-64.
[11]Liao P,Wang SQ,Wang S,Zheng M,Zheng M,Zhang SJ,Cheng H,Wang Y,Xiao RP.p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes.Circ Res,2002,90:190-6.
[12]Wang M,Sankula R,Tsai BM,Meldrum KK,Turrentine M,March KL,Brown JW,Dinarello CA,Meldrum DR.P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression.Shock,2004,21:170-4.
[13]Lewis TS,Shapiro PS,Ahn NG.Signal transduction through MAP kinase cascades.Adv Cancer Res,1998,74:49-139.
[14]Kyriakis JM,Avruch J.Sounding the alarm:protein kinase cascades activated by stress and inflammation.J Biol Chem,1996,271:24313-6.
[15]Wang X,Martindale JL,Liu Y,Holbrook NJ.The cellular response to oxidative stress:influences of mitogen-activated protein kinase signalling pathways on cell survival.Biochem J,1998,333(Pt 2):291-300.
[16]Arumugam TV,Shiels IA,Woodruff TM,Granger DN,Taylor SM.The role of the complement system in ischemia-reperfusion injury.Shock,2004,21:401-9.
[17]Cain BS,Meldrum DR,Dinarello CA,Meng X,Joo KS,Banerjee A,Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function.Crit Care Med,1999,27:1309-18.
[18]Maass DL,White J,Horton JW.IL-lbeta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma.Shock,2002,18:360-6.
[19]Sakamoto A,Matsumura J,Mii S,Gotoh Y,Ogawa R.A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production.Shock,2004,22:76-81.
[20]Wright JG,Kerr JC,Valeri CR,Hobson RW 2nd.Heparin decreases ischemia-reperfusion injury in isolated canine gracilis model.Arch Surg,1988,123:470-2.
[21]Marshall CJ.Specificity of receptor tyrosine kinase signaling:transient versus sustained extracellular signal-regulated kinase activation.Cell,1995,80:179-85.
[22]Sugden PH,Bogoyevitch MA.Intracellular signalling through protein kinases in the heart.Cardiovasc Res,1995,30:478-92.
[23]Liao S,Porter D,Scott A,Newman G,Doetschman T,Schultz Jel J.The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2:the role of JNK signaling.J Mol Cell Cardiol,2007,42:106-20.
[24]Milano G,Morel S,Bonny C,Samaja M,von Segesser LK,Nicod P,Vassalli G.A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo.Am J Physiol Heart Circ Physiol,2007,292:H1828-35.
[25]Gao F,Yue TL,Shi DW,Christopher TA,Lopez BL,Ohlstein EH,Barone FC,Ma XL.p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.Cardiovasc Res.53(2).Netherlands,2002.414-22.
[26]Kapadia S,Lee J,Torre-Amione G,Birdsall HH,Ma TS,Mann DL.Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.J Clin Invest,1995,96:1042-52.
[27]Odeh M.Tumor necrosis factor-alpha as a myocardial depressant substance.Int J Cardiol,1993,42:231-8.
[28]Meldrum DR.Tumor necrosis factor in the heart.Am J Physiol,1998,274:R577-95.
[29]Gurevitch J,Frolkis I,Yuhas Y,Paz Y,Matsa M,Mohr R,Yakirevich V.Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion.J Am Coll Cardiol,1996,28:247-52.
[30]Stambe C,Atkins RC,Hill PA,Nikolic-Paterson DJ.Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis.Kidney Int,2003,64:2121-32.
[31]Paz Y,Frolkis I,Pevni D,Shapira I,Yuhas Y,Iaina A,Wollman Y,Chernichovski T,Nesher N,Locker C,Mohr R,Uretzky G.Effect of tumor necrosis factor-alpha on endothelial and inducible nitric oxide synthase messenger ribonucleic acid expression and nitric oxide synthesis in ischemic and nonischemic isolated rat heart.J Am Coll Cardiol,2003,42:1299-305.
[32]Liu S,Wang CB,Guo SB,Yan YJ.The primary approach to untoward reactions and rational application of polysaccharide sulphate.Chinese Journal of Marine Drugs,1992,11:17-19.
[1]Levine B,Kalman J,Mayer L,Fillit HM,Packer M.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med,1990,323:236-41.
[2]Springer TA.Traffic signals for lymphocyte recirculation and leukocyte emigration:the multistep paradigm.Cell,1994,76:301-14.
[3]Mann DL.Recent insights into the role of tumor necrosis factor in the failing heart.Heart Fail Rev,2001,6:71-80.
[4]Torre-Amione G,Kapadia S,Lee J,Durand JB,Bies RD,Young JB,Mann DL.Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart.Circulation,1996,93:704-11.
[5]Mehra VC,Ramgolam VS,Bender JR.Cytokines and cardiovascular disease.J Leukoc Biol,2005,78:805-18.
[6]Prabhu SD.Cytokine-induced modulation of cardiac function.Circ Res,2004,95:1140-53.
[7]Anker SD,von Haehling S.Inflammatory mediators in chronic heart failure:an overview.Heart,2004,90:464-70.
[8]Torre-Amione G.Immune activation in chronic heart failure.Am J Cardiol,2005,95:3C-8C,discussion 38C-40C.
[9]Mann DL.Inflammatory mediators and the failing heart:past,present,and the foreseeable future.Circ Res,2002,91:988-98.
[10]Piagnerelli M,Boudjeltia KZ,Vanhaeverbeek M,Vincent JL.Red blood cell rheology in sepsis.Intensive Care Med,2003,29:1052-61.
[11]Riedemann NC,Guo RF,Neff TA,Laudes IJ,Keller KA,Sarma VJ,Markiewski MM,Mastellos D,Strey CW,Pierson CL,Lambris JD,Zetoune FS,Ward PA.Increased C5a receptor expression in sepsis.J Clin Invest,2002,110:101-8.
[12]Huber-Lang MS,Younkin EM,Sarma JV,McGuire SR,Lu KT,Guo RF,Padgaonkar VA,Curnutte JT,Erickson R,Ward PA.Complement-induced impairment of innate immunity during sepsis.J Immunol,2002,169:3223-31.
[13]Testa M,Yeh M,Lee P,Fanelli R,Loperfido F,Berman JW,LeJemtel TH.Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.J Am Coll Cardiol,1996,28:964-71.
[14]Rauchhaus M,Doehner W,Francis DP,Davos C,Kemp M,Liebenthal C,Niebauer J,Hooper J,Volk HD,Coats AJ,Anker SD.Plasma cytokine parameters and mortality in patients with chronic heart failure.Circulation,2000,102:3060-7.
[15]Matsumori A,Yamada T,Suzuki H,Matoba Y,Sasayama S.Increased circulating cytokines in patients with myocarditis and cardiomyopathy.Br Heart J,1994,72:561-6.
[16]Oren H,Erbay AR,Balci M,Cehreli S.Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction:do they affect the outcome of patients?.Angiology,2007,58:45-54.
[17]Martinez Rosas M.[Cardiac remodeling and inflammation].Arch Cardiol Mex,2006,76 Suppl 4:S58-66.
[18]Moro C,Jouan MG,Rakotovao A,Toufektsian MC,Ormezzano O,Nagy N,Tosaki A,de Leiris J,Boucher F.Delayed expression of cytokines after reperfused myocardial infarction:possible trigger for cardiac dysfunction and ventricular remodeling.Am J Physiol Heart Circ Physiol,2007,293:H3014-9.
[19]Anker SD,Egerer KR,Volk HD,Kox WJ,Poole-Wilson PA,Coats AJ.Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.Am J Cardiol,1997,79:1426-30.
[20]Genth-Zotz S,von Haehling S,Bolger AP,Kalra PR,Wensel R,Coats AJ,Anker SD.Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.Am J Cardiol,2002,90:1226-30.
[21]Niebauer J,Volk HD,Kemp M,Dominguez M,Schumann RR,Rauchhaus M,Poole-Wilson PA,Coats AJ,Anker SD.Endotoxin and immune activation in chronic heart failure:a prospective cohort study.Lancet,1999,353:1838-42.
[22]Aukrust P,Gullestad L,Ueland T,Damas JK,Yndestad A.Inflammatory and anti-inflammatory cytokines in chronic heart failure:potential therapeutic implications.Ann Med,2005,37:74-85.
[23]Vasan RS,Sullivan LM,Roubenoff R,Dinarello CA,Harris T,Benjamin EJ,Sawyer DB,Levy D,Wilson PW,D'Agostino RB.Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction:the Framingham Heart Study.Circulation,2003,107:1486-91.
[24]Torre-Amione G,Kapadia S,Benedict C,Oral H,Young JB,Mann DL.Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the Studies of Left Ventricular Dysfunction(SOLVD).J Am Coll Cardiol,1996,27:1201-6.
[25]Bozkurt B,Kribbs SB,Clubb FJ Jr,Michael LH,Didenko VV,Hornsby PJ,Seta Y,Oral H,Spinale FG,Mann DL.Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.Circulation,1998,97:1382-91.
[26]Gullestad L,Aukrust P,Ueland T,Espevik T,Yee G,Vagelos R,Froland SS,Fowler M.Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure.J Am Coll Cardiol,1999,34:2061-7.
[27]Gurlek A,Kilickap M,Dincer I,Dandachi R,Tutkak H,Oral D.Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure.J Cardiovasc Risk,2001,8:279-82.
[28]Tsutamoto T,Wada A,Matsumoto T,Maeda K,Mabuchi N,Hayashi M,Tsutsui T,Ohnishi M,Sawaki M,Fujii M,Matsumoto T,Yamamoto T,Horie H,Sugimoto Y,Kinoshita M.Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.J Am Coll Cardiol,2001,37:2086-92.
[29]Thaik CM,Calderone A,Takahashi N,Colucci WS.Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes.J Clin Invest,1995,96:1093-9.
[30]Kubota T,McTiernan CF,Frye CS,Slawson SE,Lemster BH,Koretsky AP,Demetris AJ,Feldman AM.Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.Circ Res,1997,81:627-35.
[31]Seta Y,Shan K,Bozkurt B,Oral H,Mann DL.Basic mechanisms in heart failure:the cytokine hypothesis.J Card Fail,1996,2:243-9.
[32]Eddy LJ,Goeddel DV,Wong GH.Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury.Biochem Biophys Res Commun,1992,184:1056-9.
[33]Wong GH,Goeddel DV.Induction of manganous superoxide dismutase by tumor necrosis factor:possible protective mechanism.Science,1988,242:941-4.
[34]Nakano M,Knowlton AA,Yokoyama T,Lesslauer W,Mann DL.Tumor necrosis factor-alpha-induced expression of heat shock protein 72 in adult feline cardiac myocytes.Am J Physiol,1996,270:H1231-9.
[35]Plumier JC,Ross BM,Currie RW,Angelidis CE,Kazlaris H,Kollias G,Pagoulatos GN.Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery.J Clin Invest,1995,95:1854-60.
[36]Deswal A,Petersen NJ,Feldman AM,Young JB,White BG,Mann DL.Cytokines and cytokine receptors in advanced heart failure:an analysis of the cytokine database from the Vesnarinone trial(VEST).Circulation,2001,103:2055-9.
[37]Tracey KJ,Beutler B,Lowry SF,Merryweather J,Wolpe S,Milsark IW,Hariri RJ,Fahey TJ 3rd,Zentella A,Albert JD,et al.Shock and tissue injury induced by recombinant human cachectin.Science,1986,234:470-4.
[38]Natanson C,Eichenholz PW,Danner RL,Eichacker PQ,Hoffman WD,Kuo GC,Banks SM,MacVittie TJ,Parrillo JE.Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.J Exp Med,1989,169:823-32.
[39]Pagani FD,Baker LS,Hsi C,Knox M,Fink MP,Visner MS.Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.J Clin Invest,1992,90:389-98.
[40]Franco F,Thomas GD,Giroir B,Bryant D,Bullock MC,Chwialkowski MC,Victor RG,Peshock RM.Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.Circulation,1999,99:448-54.
[41]Meldrum DR.Tumor necrosis factor in the heart.Am J Physiol,1998,274:R577-95.
[42]Gulick T,Chung MK,Pieper SJ,Lange LG,Schreiner GF.Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness.Proc Natl Acad Sci U S A,1989,86:6753-7.
[43]Balligand JL,Ungureanu D,Kelly RA,Kobzik L,Pimental D,Michel T,Smith TW.Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium.J Clin Invest,1993,91:2314-9.
[44]Kinugawa K,Takahashi T,Kohmoto O,Yao A,Aoyagi T,Momomura S,Hirata Y,Serizawa T.Nitric oxide-mediated effects of interleukin-6 on[Ca2+]i and cell contraction in cultured chick ventricular myocytes.Circ Res,1994,75:285-95.
[45]Hosenpud JD,Campbell SM,Mendelson DJ.Interleukin-1-induced myocardial depression in an isolated beating heart preparation.J Heart Transplant,1989,8:460-4.
[46]Finkel MS,Oddis CV,Jacob TD,Watkins SC,Hattler BG,Simmons RL.Negative inotropic effects of cytokines on the heart mediated by nitric oxide.Science,1992,257:387-9.
[47]Panas D,Khadour FH,Szabo C,Schulz R.Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism.Am J Physiol,1998,275:H1016-23.
[48]Kumar A,Brar R,Wang P,Dee L,Skorupa G,Khadour F,Schulz R,Parrillo JE.Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility.Am J Physiol,1999,276:R265-76.
[49]Dinarello CA.Interleukin-18.Methods,1999,19:121-32.
[50]Pomerantz BJ,Reznikov LL,Harken AH,Dinarello CA.Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-lbeta.Proc Natl Acad Sci U S A,2001,98:2871-6.
[51]Yokoyama T,Nakano M,Bednarczyk JL,Mclntyre BW,Entman M,Mann DL.Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes.Circulation,1997,95:1247-52.
[52]Krown KA,Page MT,Nguyen C,Zechner D,Gutierrez V,Comstock KL,Glembotski CC,Quintana PJ,Sabbadini RA.Tumor necrosis factor alphainduced apoptosis in cardiac myocytes.Involvement of the sphingolipid signaling cascade in cardiac cell death.J Clin Invest,1996,98:2854-65.
[53]Bryant D,Becker L,Richardson J,Shelton J,Franco F,Peshock R,Thompson M, Giroir B.Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.Circulation,1998,97:1375-81.
[54]Sivasubramanian N,Coker ML,Kurrelmeyer KM,MacLellan WR,DeMayo FJ,Spinale FG,Mann DL.Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.Circulation,2001,104:826-31.
[55]Li YY,Feng YQ,Kadokami T,McTiernan CF,Draviam R,Watkins SC,Feldman AM.Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.Proc Natl Acad Sci U S A,2000,97:12746-51.
[56]Weber KT.Cardiac interstitium in health and disease:the fibrillar collagen network.J Am Coll Cardiol,1989,13:1637-52.
[57]Knittel T,Mehde M,Grundmann A,Saile B,Scharf JG,Ramadori G.Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.Histochem Cell Biol,2000,113:443-53.
[58]Sime PJ,Marr RA,Gauldie D,Xing Z,Hewlett BR,Graham FL,Gauldie J.Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-betal and myofibroblasts.Am J Pathol,1998,153:825-32.
[59]Agnoletti L,Curello S,Bachetti T,Malacarne F,Gaia G,Comini L,Volterrani M,Bonetti P,Parrinello G,Cadei M,Grigolato PG,Ferrari R.Serum from patients with severe heart failure downregulates eNOS and is proapoptotic:role of tumor necrosis factor-alpha.Circulation,1999,100:1983-91.
[60]Anker SD,Volterrani M,Egerer KR,Felton CV,Kox WJ,Poole-Wilson PA,Coats AJ.Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure.QJM,1998,91:199-203.
[61]Fichtlscherer S,Rossig L,Breuer S,Vasa M,Dimmeler S,Zeiher AM.Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.Circulation,2001,104:3023-5.
[62]Kapadia S,Lee J,Torre-Amione G,Birdsall HH,Ma TS,Mann DL.Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.J Clin Invest,1995,96:1042-52.
[63]Torre-Amione G,Kapadia S,Lee J,Bies RD,Lebovitz R,Mann DL.Expression and functional significance of tumor necrosis factor receptors in human myocardium.Circulation,1995,92:1487-93.
[64]Bolger AP,Anker SD.Tumour necrosis factor in chronic heart failure:a peripheral view on pathogenesis,clinical manifestations and therapeutic implications.Drugs,2000,60:1245-57.
[65]von Haehling S,Jankowska EA,Anker SD.Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications.Basic Res Cardiol,2004,99:18-28.
[66]Torre-Amione G,Bozkurt B,Deswal A,Mann DL.An overview of tumor necrosis factor alpha and the failing human heart.Curr Opin Cardiol,1999,14:206-10.
[67]Feldman AM,Combes A,Wagner D,Kadakomi T,Kubota T,Li YY,McTiernan C.The role of tumor necrosis factor in the pathophysiology of heart failure.J Am Coll Cardiol,2000,35:537-44.
[68]Dinarello CA,Cannon JG,Wolff SM,Bernheim HA,Beutler B,Cerami A,Figari IS,Palladino MA Jr,O'Connor JV.Tumor necrosis factor(cachectin) is an endogenous pyrogen and induces production of interleukin 1.J Exp Med,1986,163:1433-50.
[69]Nakano M,Knowlton AA,Dibbs Z,Mann DL.Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation,1998,97:1392-400.
[70]Nagueh SF,Stetson SJ,Lakkis NM,Killip D,Perez-Verdia A,Entman ML,Spencer WH 3rd,Torre-Amione G.Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy.Circulation,2001,103:1844-50.
[71]Kapadia SR,Yakoob K,Nader S,Thomas JD,Mann DL,Griffin BP.Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload.J Am Coll Cardiol,2000,36:208-12.
[72]Sacher RA.Intravenous immunoglobulin consensus statement.J Allergy Clin Immunol,2001,108:S139-46.
[73]Murray DR,Freeman GL.Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs.Circ Res,1996,78:154-60.
[74]Dibbs Z,Thornby J,White BG,Mann DL.Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure:implications for clinical trials.J Am Coll Cardiol,1999,33:1935-42.
[75]Kapadia S,Torre-Amione G,Mann DL.Pitfalls in measuring cytokines.Ann Intern Med,1994,121:149-50.
[76]Kumar A,Haery C,Parrillo JE.Myocardial dysfunction in septic shock.Crit Care Clin,2000,16:251-87.
[77]Parrillo JE,Burch C,Shelhamer JH,Parker MM,Natanson C,Schuette W.A circulating myocardial depressant substance in humans with septic shock.Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.J Clin Invest,1985,76:1539-53.
[78]Kumar A,Wood K,Parrillo JE.Circulating substances and energy metabolism in septic shock.Crit Care Med,2003,31:632-3.
[79]Cain BS,Meldrum DR,Dinarello CA,Meng X,Joo KS,Banerjee A,Harken AH.Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function.Crit Care Med,1999,27:1309-18.
[80]El-Menyar AA.The resuscitation outcome:revisit the story of the stony heart.Chest,2005,128:2835-46.
[81]El-Menyar AA.Pathophysiology and hemodynamic of postresuscitation syndrome.Saudi Med J,2006,27:441-5.
[82]Sharma HS,Das DK.Role of cytokines in myocardial ischemia and reperfusion.Mediators Inflamm,1997,6:175-83.
[83]Niemann JT,Garner D,Lewis RJ.Tumor necrosis factor-alpha is associated with early postresuscitation myocardial dysfunction.Crit Care Med,2004,32:1753-8.
[84]van Deventer SJ,Buller HR,ten Cate JW,Aarden LA,Hack CE,Sturk A.Experimental endotoxemia in humans:analysis of cytokine release and coagulation,fibrinolytic,and complement pathways.Blood,1990,76:2520-6.
[85]Ng SB,Tan YH,Guy GR.Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.J Biol Chem,1994,269:19021-7.
[86]Sanceau J,Kaisho T,Hirano T,Wietzerbin J.Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1,NF kappa B,and Sp1 transcription factors.J Biol Chem,1995,270:27920-31.
[87]Baumann H,Gauldie J.Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation.Mol Biol Med,1990,7:147-59.
[88]Heinrich PC,Castell JV,Andus T.Interleukin-6 and the acute phase response.Biochem J,1990,265:621-36.
[89]Tsutamoto T,Hisanaga T,Wada A,Maeda K,Ohnishi M,Fukai D,Mabuchi N,Sawaki M,Kinoshita M.Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure,and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.J Am Coll Cardiol,1998,31:391-8.
[90]Mohler ER 3rd,Sorensen LC,Ghali JK,Schocken DD,Willis PW,Bowers JA,Cropp AB,Pressler ML.Role of cytokines in the mechanism of action of amlodipine:the PRAISE Heart Failure Trial.Prospective Randomized Amlodipine Survival Evaluation.J Am Coll Cardiol,1997,30:35-41.
[91]Sugishita K,Kinugawa K,Shimizu T,Harada K,Matsui H,Takahashi T,Serizawa T,Kohmoto O.Cellular basis for the acute inhibitory effects of IL-6 and TNF-alpha on excitation-contraction coupling.J Mol Cell Cardiol,1999,31:1457-67.
[92]Maeda K,Tsutamoto T,Wada A,Mabuchi N,Hayashi M,Tsutsui T,Ohnishi M,Sawaki M,Fujii M,Matsumoto T,Kinoshita M.High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.J Am Coll Cardiol,2000,36:1587-93.
[93]Bolger AP,Sharma R,von Haehling S,Doehner W,Oliver B,Rauchhaus M,Coats AJ,Adcock IM,Anker SD.Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.Am J Cardiol,2002,90:384-9.
[94]Nishio R,Matsumori A,Shioi T,Ishida H,Sasayama S.Treatment of experimental viral myocarditis with interleukin-10.Circulation,1999,100:1102-8.
[95]Gullestad L,Aass H,Fjeld JG,Wikeby L,Andreassen AK,Ihlen H,Simonsen S,Kjekshus J,Nitter-Hauge S,Ueland T,Lien E,Froland SS,Aukrust P.Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.Circulation,2001,103:220-5.
[96]Kaur K,Sharma AK,Singal PK.Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction.Am J Physiol Heart Circ Physiol,2006,291:H106-13.
[97]Nishii M,Inomata T,Takehana H,Takeuchi I,Nakano H,Koitabashi T,Nakahata J,Aoyama N,Izumi T.Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis.J Am Coll Cardiol,2004,44:1292-7.
[98]Kaneko K,Kanda T,Yamauchi Y,Hasegawa A,Iwasaki T,Arai M,Suzuki T,Kobayashi I,Nagai R.C-Reactive protein in dilated cardiomyopathy.Cardiology,1999,91:215-9.
[99]Anand IS,Latini R,Florea VG,Kuskowski MA,Rector T,Masson S,Signorini S,Mocarelli P,Hester A,Glazer R,Cohn JN.C-reactive protein in heart failure:prognostic value and the effect of valsartan.Circulation,2005,112:1428-34.
[100]Grabellus F,Levkau B,Sokoll A,Welp H,Schmid C,Deng MC,Takeda A,Breithardt G,Baba HA.Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support.Cardiovasc Res,2002,53:124-30.
[101]Tsutamoto T,Hisanaga T,Fukai D,Wada A,Maeda Y,Maeda K,Kinoshita M.Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure.Am J Cardiol,1995,76:803-8.
[102]Andreassen AK,Nordoy I,Simonsen S,Ueland T,Muller F,Froland SS,Gullestad L,Aukrust P.Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation.Am J Cardiol,1998,81:604-8.
[103]Devaux B,Scholz D,Hirche A,Klovekorn WP,Schaper J.Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure.Eur Heart J,1997,18:470-9.
[104]Drexler H,Hornig B.Endothelial dysfunction in human disease.J Mol Cell Cardiol,1999,31:51-60.
[105]Satoh M,Nakamura M,Tamura G,Makita S,Segawa I,Tashiro A,Satodate R,Hiramori K.Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy.J Am Coll Cardiol,1997,29:716-24.
[106]Heymes C,Vanderheyden M,Bronzwaer JG,Shah AM,Paulus WJ.Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy.Circulation,1999,99:3009-16.
[107]Doing A,Griffin D,Jacobson JA,Amber IJ,Gilbert E.B-cell function in chronic heart failure:antibody response to pneumococcal vaccine.J Card Fail,2001,7:318-21.
[108]Sliwa K,Skudicky D,Candy G,Wisenbaugh T,Sareli P.Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.Lancet,1998,351:1091-3.
[109]Deswal A,Bozkurt B,Seta Y,Parilti-Eiswirth S,Hayes FA,Blosch C,Mann DL.Safety and efficacy of a soluble P75 tumor necrosis factor receptor(Enbrel,etanercept) in patients with advanced heart failure.Circulation,1999,99:3224-6.
[110]Bozkurt B,Torre-Amione G,Warren MS,Whitmore J,Soran OZ,Feldman AM,Mann DL.Results of targeted anti-tumor necrosis factor therapy with etanercept(ENBREL) in patients with advanced heart failure.Circulation,2001,103:1044-7.
[111]Mann DL,McMurray JJ,Packer M,Swedberg K,Borer JS,Colucci WS,Djian J,Drexler H,Feldman A,Kober L,Krum H,Liu P,Nieminen M,Tavazzi L,van Veldhuisen DJ,Waldenstrom A,Warren M,Westheim A,Zannad F,Fleming T.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation(RENEWAL).Circulation,2004,109:1594-602.
[112]Anker SD,Coats AJ.How to RECOVER from RENAISSANCE?The significance of the results of RECOVER,RENAISSANCE,RENEWAL and ATTACH.Int J Cardiol,2002,86:123-30.
[113]Chung ES,Packer M,Lo KH,Fasanmade AA,Willerson JT.Randomized,double-blind,placebo-controlled,pilot trial of infliximab,a chimeric monoclonal antibody to tumor necrosis factor-alpha,in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure(ATTACH) trial.Circulation,2003,107:3133-40.
[114]Samuelsson A,Towers TL,Ravetch JV.Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.Science,2001,291:484-6.
[115]McNamara DM,Holubkov R,Starling RC,Dec GW,Loh E,Torre-Amione G,Gass A,Janosko K,Tokarczyk T,Kessler P,Mann DL,Feldman AM.Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.Circulation,2001,103:2254-9.
[116]Fadok VA,Bratton DL,Konowal A,Freed PW,Westcott JY,Henson PM.Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta,PGE2,and PAF.J Clin Invest,1998,101:890-8.
[117]Voll RE,Herrmann M,Roth EA,Stach C,Kalden JR,Girkontaite I.Immunosuppressive effects of apoptotic cells.Nature,1997,390:350-1.
[118]Babaei S,Stewart DJ,Picard P,Monge JC.Effects of VasoCare therapy on the initiation and progression of atherosclerosis.Atherosclerosis,2002,162:45-53.
[119]Torre-Amione G,Sestier F,Radovancevic B,Young J.Effects of a novel immune modulation therapy in patients with advanced chronic heart failure:results of a randomized,controlled,phase Ⅱ trial.J Am Coll Cardiol,2004,44:1181-6.
[120]Torre-Amione G,Bourge RC,Colucci WS,Greenberg B,Pratt C,Rouleau JL, Sestier F,Moye LA,Geddes JA,Nemet AJ,Young JB.A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure:the ACCLAIM trial rationale and design.Can J Cardiol,2007,23:369-76.
[121]Muller J,Wallukat G,Dandel M,Bieda H,Brandes K,Spiegelsberger S,Nissen E,Kunze R,Hetzer R.Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.Circulation,2000,101:385-91.
[122]von Haehling S,Anker SD,Bassenge E.Statins and the role of nitric oxide in chronic heart failure.Heart Fail Rev,2003,8:99-106.
[123]Hernandez-Perera O,Perez-Sala D,Navarro-Antolin J,Sanchez-Pascuala R,Hernandez G,Diaz C,Lamas S.Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,atorvastatin and simvastatin,on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.J Clin Invest,1998,101:2711-9.
[124]Laufs U,La Fata V,Plutzky J,Liao JK.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.Circulation,1998,97:1129-35.
[125]Node K,Fujita M,Kitakaze M,Hori M,Liao JK.Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy.Circulation,2003,108:839-43.
[126]Rauchhaus M,Coats AJ,Anker SD.The endotoxin-lipoprotein hypothesis.Lancet,2000,356:930-3.
[127]Tousoulis D,Antoniades C,Bosinakou E,Kotsopoulou M,Pitsavos C,Vlachopoulos C,Panagiotakos D,Stefanadis C.Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.Atherosclerosis,2005,178:359-63.
[128]Tousoulis D,Antoniades C,Bosinakou E,Kotsopoulou M,Tsioufis C,Tentolouris C,Trikas A,Pitsavos C,Stefanadis C.Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.Heart,2005,91:27-31.
[129]Strey CH,Young JM,Molyneux SL,George PM,Florkowski CM,Scott RS,Frampton CM.Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.Atherosclerosis,2005,179:201-6.
[130]Angermann CE,Nitschmann S.[Statin therapy for systolic heart failure.The CORONA trial(Controlled Rosuvastatin Multinational Trial in Heart Failure).].Internist(Berl) 2008.
[131]Tavazzi L,Tognoni G,Franzosi MG,Latini R,Maggioni AP,Marchioli R,Nicolosi GL,Porcu M.Rationale and design of the GISSI heart failure trial:a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.Eur J Heart Fail,2004,6:635-41.
[132]Kjekshus J,Dunselman P,Blideskog M,Eskilson C,Hjalmarson A,McMurray JV,Waagstein F,Wedel H,Wessman P,Wikstrand J.A statin in the treatment of heart failure?Controlled rosuvastatin multinational study in heart failure(CORONA):study design and baseline characteristics.Eur J Heart Fail,2005,7:1059-69.
[133]Fonarow GC.Randomized clinical outcome trials of statins in heart failure.Heart Fail Clin,2008,4:225-9.
[134]Gissi-HF Investigators,Tavazzi L,Maggioni AP,Marchioli R,Barlera S,Franzosi MG,Latini R,Lucci D,Nicolosi GL,Porcu M,Tognoni G.Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial):a randomised,double-blind,placebo-controlled trial.Lancet,2008,372:1231-9.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |